302 results on '"Labreuche, J."'
Search Results
2. OC 60.3 Prevention of Hemorrhage after Implantation of Mechanical Circulatory Support with a Purified Von Willebrand Factor Concentrate: Results of the Early Terminated Randomized Controlled PHAM Trial
- Author
-
Rauch, A., primary, Lebreton, G., additional, Moussa, M., additional, Vincentelli, A., additional, Flecher, E., additional, Bouchot, O., additional, Dambrin, C., additional, Rozec, B., additional, Barandon, L., additional, Jeanpierre, E., additional, Ajzenberg, N., additional, Repessé, Y., additional, De Maistre, E., additional, Boissier, E., additional, Smadja, D., additional, Nedelec-Gac, F., additional, Voisin, S., additional, Laporte, S., additional, Labreuche, J., additional, and Susen, S., additional
- Published
- 2023
- Full Text
- View/download PDF
3. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma‐induced coagulopathy: a randomized open‐label trial
- Author
-
Garrigue, D., Godier, A., Glacet, A., Labreuche, J., Kipnis, E., Paris, C., Duhamel, A., Resch, E., Bauters, A., Machuron, F., Renom, P., Goldstein, P., Tavernier, B., Sailliol, A., and Susen, S.
- Published
- 2018
- Full Text
- View/download PDF
4. Effect of Endovascular Contact Aspiration vs Stent Retriever on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion. The ASTER Randomized Clinical Trial
- Author
-
Lapergue, B., Blanc, R., Gory, B., Labreuche, J., Duhamel, A., and Marnat, G.
- Published
- 2017
- Full Text
- View/download PDF
5. Trial of Deferiprone in Parkinson's Disease
- Author
-
Devos, D., Labreuche, J., Rascol, O., Corvol, J.C., Duhamel, A., Delannoy, P. Guyon, Poewe, W., Compta, Y., Pavese, N., Růžička, E., Dušek, P., Post, B., Bloem, B.R., Berg, D., Maetzler, W., Otto, M., Habert, M.O., Lehericy, S., Ferreira, J., Dodel, R., Tranchant, C., Eusebio, A., Thobois, S., Marques, A.R., Meissner, W.G., Ory-Magne, F., Walter, U., Bie, R.M. de, Gago, M., Vilas, D., Kulisevsky, J., Januario, C., Coelho, M.V.S., Behnke, S., Worth, P., Seppi, K., Ouk, T., Potey, C., Leclercq, C., Viard, R., Kuchcinski, G., Lopes, R., Pruvo, J.P., Pigny, P., Garçon, G., Simonin, O., Carpentier, J., Rolland, A.S., Nyholm, D., Scherfler, C., Mangin, J.F., Chupin, M., Bordet, R., Dexter, D.T., Fradette, C., Spino, M., Tricta, F., Ayton, S., Bush, A.I., Devedjian, J.C., Duce, J.A., Cabantchik, I., Defebvre, L., Deplanque, D., Moreau, C., Devos, D., Labreuche, J., Rascol, O., Corvol, J.C., Duhamel, A., Delannoy, P. Guyon, Poewe, W., Compta, Y., Pavese, N., Růžička, E., Dušek, P., Post, B., Bloem, B.R., Berg, D., Maetzler, W., Otto, M., Habert, M.O., Lehericy, S., Ferreira, J., Dodel, R., Tranchant, C., Eusebio, A., Thobois, S., Marques, A.R., Meissner, W.G., Ory-Magne, F., Walter, U., Bie, R.M. de, Gago, M., Vilas, D., Kulisevsky, J., Januario, C., Coelho, M.V.S., Behnke, S., Worth, P., Seppi, K., Ouk, T., Potey, C., Leclercq, C., Viard, R., Kuchcinski, G., Lopes, R., Pruvo, J.P., Pigny, P., Garçon, G., Simonin, O., Carpentier, J., Rolland, A.S., Nyholm, D., Scherfler, C., Mangin, J.F., Chupin, M., Bordet, R., Dexter, D.T., Fradette, C., Spino, M., Tricta, F., Ayton, S., Bush, A.I., Devedjian, J.C., Duce, J.A., Cabantchik, I., Defebvre, L., Deplanque, D., and Moreau, C.
- Abstract
Item does not contain fulltext, BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In parti
- Published
- 2022
6. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
- Author
-
Desoutter, J, Gay, J, Berthon, C, Ades, L, Gruson, B, Geffroy, S, Plantier, I, Marceau, A, Helevaut, N, Fernandes, J, Bemba, M, Stalnikiewicz, L, Frimat, C, Labreuche, J, Nibourel, O, Roumier, C, Figeac, M, Fenaux, P, Quesnel, B, Renneville, A, Duhamel, A, and Preudhomme, C
- Published
- 2016
- Full Text
- View/download PDF
7. Joint latent class model:Simulation study of model properties and application to amyotrophic lateral sclerosis disease
- Author
-
Kyheng, M. (MaÉva), Babykina, G. (Génia), Ternynck, C. (Camille), DEVOS, D. (DAVID), Labreuche, J. (Julien), Duhamel, A. (Alain), Université de Lille, CHU Lille, and Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
- Subjects
Amyotrophic lateral sclerosis ,Joint model ,Latent classes ,Linear mixed model ,MLE properties ,Monte Carlo simulations ,Survival analysis - Abstract
In many clinical applications, evolution of a longitudinal marker is censored by an event occurrence, and, symmetrically, event occurrence can be influenced by the longitudinal marker evolution. In such frameworks joint modeling is of high interest. The Joint Latent Class Model (JLCM) allows to stratify the population into groups (classes) of patients that are homogeneous both with respect to the evolution of a longitudinal marker and to the occurrence of an event; this model is widely employed in real-life applications. However, the finite sample-size properties of this model remain poorly explored. In the present paper, a simulation study is carried out to assess the impact of the number of individuals, of the censoring rate and of the degree of class separation on the finite sample size properties of the JLCM. A real-life application from the neurology domain is also presented. This study assesses the precision of class membership prediction and the impact of covariates omission on the model parameter estimates. Simulation study reveals some departures from normality of the model for survival sub-model parameters. The censoring rate and the number of individuals impact the relative bias of parameters, especially when the classes are weakly distinguished. In real-data application the observed heterogeneity on individual profiles in terms of a longitudinal marker evolution and of the event occurrence remains after adjusting to clinically relevant and available covariates; CONCLUSION: The JLCM properties have been evaluated. We have illustrated the discovery in practice and highlights the usefulness of the joint models with latent classes in this kind of data even with pre-specified factors. We made some recommendations for the use of this model and for future research. 21;1
- Published
- 2021
8. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling
- Author
-
Decanter, C, primary, Delepine, J, additional, Behal, H, additional, Manier, S, additional, Bruno, B, additional, Barbatti, M, additional, Robin, C, additional, Labreuche, J, additional, Morschhauser, F, additional, and Pigny, P, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Impact of a targeted isolation strategy at intensive-care-unit-admission on intensive-care-unit-acquired infection related to multidrug-resistant bacteria: a prospective uncontrolled before–after study
- Author
-
Ledoux, G., Six, S., Lawson, R., Labreuche, J., Blazejewski, C., Wallet, F., Duhamel, A., and Nseir, S.
- Published
- 2016
- Full Text
- View/download PDF
10. Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion
- Author
-
Anadani, M. Marnat, G. Consoli, A. Papanagiotou, P. Nogueira, R.G. Spiotta, A.M. Bourcier, R. Kyheng, M. Labreuche, J. Siddiqui, A.H. Ribo, M. De Havenon, A. Fischer, U. Sibon, I. Dargazanli, C. Arquizan, C. Cognard, C. Olivot, J.M. Anxionnat, R. Audibert, G. Mazighi, M. Blanc, R. Lapergue, B. Richard, S. Gory, B.
- Abstract
Background: Endovascular therapy (EVT) is effective and safe in patients with tandem occlusion. The benefit of intravenous thrombolysis (IVT) prior to EVT in acute tandem occlusion is debatable. Objective: To compare EVT alone with EVT plus IVT in patients with acute ischemic stroke due to anterior circulation tandem occlusions. Methods: This is an individual patient pooled analysis of the Thrombectomy In TANdem lesions (TITAN) and Endovascular Treatment in Ischemic Stroke (ETIS) Registries. Patients were divided into two groups based on prior IVT treatment: (1) IVT+ group, which included patients who received IVT prior to EVT, (2) IVT- group, which included patients who did not receive IVT prior to EVT. Propensity score (inverse probability of treatment weighting (IPTW)) was used to reduce baseline between-group differences. The primary outcome was favorable outcome - that is, modified Rankin Scale (mRS) score 0 to 2 at 90 days. Results: Overall, 602 consecutive patients with an acute stroke with tandem occlusion were included (380 and 222 in the bridging therapy and EVT alone groups, respectively). Onset to imaging time was shorter in the IVT+ group (median 103 vs 140 min). In contrast, imaging to puncture time was longer in the IVT+ group (median 107 vs 91 min). In IPTW analysis, the IVT+ group had higher odds of favorable outcome, excellent outcome (90-day mRS score 0-1), and successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b/3 at the end of EVT). There was no difference in the risk of significant hemorrhagic complications between groups. In secondary analysis of patients treated with acute cervical internal carotid artery stenting, bridging therapy was associated with higher odds of favorable outcome and lower odds of mortality at 90 days. Conclusions: Our results suggest that bridging therapy in patients with acute ischemic stroke due to anterior tandem occlusion is safe and may improve functional outcome, even in the setting of acute cervical internal carotid artery stenting during EVT. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
- Published
- 2021
11. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
- Author
-
Rouzé, A. Martin-Loeches, I. Povoa, P. Makris, D. Artigas, A. Bouchereau, M. Lambiotte, F. Metzelard, M. Cuchet, P. Boulle Geronimi, C. Labruyere, M. Tamion, F. Nyunga, M. Luyt, C.-E. Labreuche, J. Pouly, O. Bardin, J. Saade, A. Asfar, P. Baudel, J.-L. Beurton, A. Garot, D. Ioannidou, I. Kreitmann, L. Llitjos, J.-F. Magira, E. Mégarbane, B. Meguerditchian, D. Moglia, E. Mekontso-Dessap, A. Reignier, J. Turpin, M. Pierre, A. Plantefeve, G. Vinsonneau, C. Floch, P.-E. Weiss, N. Ceccato, A. Torres, A. Duhamel, A. Nseir, S. Favory, R. Preau, S. Jourdain, M. Poissy, J. Bouras, C. Saint Leger, P. Fodil, H. Aptel, F. Van Der Linden, T. Thille, A.W. Azoulay, E. Pène, F. Razazi, K. Bagate, F. Contou, D. Voiriot, G. Thevenin, D. Guidet, B. Le Guennec, L. Kouatchet, A. Ehrmann, S. Brunin, G. Morawiec, E. Boyer, A. Argaud, L. Voicu, S. Nieszkowska, A. Kowalski, B. Goma, G. Diaz, E. Morales, L. Tsolaki, V. Gtavriilidis, G. Mentzelopoulos, S.D. Nora, D. Boyd, S. Coelho, L. Maizel, J. Du Cheyron, D. Imouloudene, M. Quenot, J.-P. Guilbert, A. Cilloniz, C. on behalf of the coVAPid study Group
- Subjects
respiratory tract diseases - Abstract
Purpose: Although patients with SARS-CoV-2 infection have several risk factors for ventilator-associated lower respiratory tract infections (VA-LRTI), the reported incidence of hospital-acquired infections is low. We aimed to determine the relationship between SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, and the incidence of VA-LRTI. Methods: Multicenter retrospective European cohort performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation > 48 h were eligible if they had: SARS-CoV-2 pneumonia, influenza pneumonia, or no viral infection at ICU admission. VA-LRTI, including ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), were diagnosed using clinical, radiological and quantitative microbiological criteria. All VA-LRTI were prospectively identified, and chest-X rays were analyzed by at least two physicians. Cumulative incidence of first episodes of VA-LRTI was estimated using the Kalbfleisch and Prentice method, and compared using Fine-and Gray models. Results: 1576 patients were included (568 in SARS-CoV-2, 482 in influenza, and 526 in no viral infection groups). VA-LRTI incidence was significantly higher in SARS-CoV-2 patients (287, 50.5%), as compared to influenza patients (146, 30.3%, adjusted sub hazard ratio (sHR) 1.60 (95% confidence interval (CI) 1.26 to 2.04)) or patients with no viral infection (133, 25.3%, adjusted sHR 1.7 (95% CI 1.2 to 2.39)). Gram-negative bacilli were responsible for a large proportion (82% to 89.7%) of VA-LRTI, mainly Pseudomonas aeruginosa, Enterobacter spp., and Klebsiella spp. Conclusions: The incidence of VA-LRTI is significantly higher in patients with SARS-CoV-2 infection, as compared to patients with influenza pneumonia, or no viral infection after statistical adjustment, but residual confounding may still play a role in the effect estimates. © 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2021
12. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort
- Author
-
Nseir, S. Martin-Loeches, I. Povoa, P. Metzelard, M. Du Cheyron, D. Lambiotte, F. Tamion, F. Labruyere, M. Makris, D. Boulle Geronimi, C. Pinetonde Chambrun, M. Nyunga, M. Pouly, O. Mégarbane, B. Saade, A. Gomà, G. Magira, E. Llitjos, J.-F. Torres, A. Ioannidou, I. Pierre, A. Coelho, L. Reignier, J. Garot, D. Kreitmann, L. Baudel, J.-L. Voiriot, G. Contou, D. Beurton, A. Asfar, P. Boyer, A. Thille, A.W. Mekontso-Dessap, A. Tsolaki, V. Vinsonneau, C. Floch, P.-E. Le Guennec, L. Ceccato, A. Artigas, A. Bouchereau, M. Labreuche, J. Duhamel, A. Rouzé, A. coVAPid study group
- Subjects
respiratory tract diseases - Abstract
BACKGROUND: Patients with SARS-CoV-2 infection are at higher risk for ventilator-associated pneumonia (VAP). No study has evaluated the relationship between VAP and mortality in this population, or compared this relationship between SARS-CoV-2 patients and other populations. The main objective of our study was to determine the relationship between VAP and mortality in SARS-CoV-2 patients. METHODS: Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox's regression models, with cause-specific hazard for duration of mechanical ventilation and ICU stay, were used to compare outcomes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortality as competing event. FINDINGS: Of 1576 included patients, 568 were SARS-CoV-2 pneumonia, 482 influenza pneumonia, and 526 no evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 (adjusted HR 1.70 (95% CI 1.16-2.47), p = 0.006), and influenza groups (1.75 (1.03-3.02), p = 0.045), but not in the no viral infection group (1.07 (0.64-1.78), p = 0.79). VAP was associated with significantly longer duration of mechanical ventilation in the SARS-CoV-2 group, but not in the influenza or no viral infection groups. VAP was associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was not different between study groups. INTERPRETATION: VAP was associated with significantly increased 28-day mortality rate in SARS-CoV-2 patients. However, SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify the relationship between VAP and 28-day mortality. CLINICAL TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov, number NCT04359693.
- Published
- 2021
13. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
- Author
-
Amarenco P, Kim J, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha J, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim Y, Lapergue B, Lavallee P, Lee B, Lee K, Leys D, Mahagne M, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg P, Sung S, Touboul P, Touze E, Varenne O, Vicaut E, Yelles N, Bruckert E, Treat Stroke Target Investigators, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Asan Medical Center [Seoul], University of Ulsan, Santé Publique : épidémiologie et qualité des soins (EA 2694), Faculté de Médecine Henri Warembourg - Université de Lille-Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université de Bourgogne (UB), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Catholic University of Korea, Hôpital Foch [Suresnes], Hallym University Sacred Heart Hospital [Anyang, South Korea] (HUS2H), Soonchunhyang University [Asan], CHU Lille, Hôpital Pasteur [Nice] (CHU), Hospices Civils de Lyon (HCL), Centre Hospitalier de Versailles André Mignot (CHV), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Pusan National University Hospital, Physiopathologie et imagerie des troubles neurologiques (PhIND), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), GIP Cyceron (Cyceron), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Cardiologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), CHU Amiens-Picardie, and Treat Stroke to Target Investigators: Pierre Amarenco, Eric Bruckert, Maurice Giroud, Jong S Kim, Julien Labreuche, Byung-Chul Lee, Marie-Hélène Mahagne, Norbert Nighoghossian, Philippe Gabriel Steg, Pierre-Jean Touboul, Eric Vicaut, Didier Leys, Philippa Lavallée, Gregory Ducrocq, Jérémy Abtan, Olivier Varenne, Agnes Kemmel, Fausta Syana, Manele Ledra, Tharani Nagasara, Mervette Ledjeroud, Bahous Samia, Hafirassou Hadia, Benyoub Hazare, Ikrame El Jaghouni, Nessima Yelles, Sofia Zemouri, Mervette Ladjeroud, Salim Kerai, YunJeong In, Elena Meseguer, Philippa C Lavallée, Cristina Hobeanu, Celine Guidoux, Lucie Cabrejo, Jaime Gonzalez-Valcarcel, Ricardo Rigual, Gaia Sirimarco, Anna Martin-Bechet, Elena Viedma, Ioan Avram, Yves Samson, Charlotte Rosso, Sophie Crozier, Sara Leder, Anne Léger, Sandrine Deltour, Chiara Zavanone, Flore Baronnet, Christine Pires, Bertrand Lapergue, Adrien Wang, Serge Evrard, Maya Tchikviladze, Frédéric Bourdain, Delphine Lopez, Fernando Pico, Laetitia Bayon de la Tour, Marie-Laure Chadenat, Duc Long Duong, Solène Genty, Catherine Hirel, Gurkan Mutlu, Chantal Nifle, Jérôme Servan, Daniela Stanciu, Veronica Sudacevschi, Mélissa Tir, Anne-Cécile Troussière, Jennifer Yeung, Anne-Céline Zeghoudi, Ikram Tidafi-Bayou, Sylvain Lachaud, Tae-Hee Cho, Laura Mechtouff, Thomas Ritzenthaller, Laurent Derex, Carlo Albanesi, Elodie Ong, Amandine Benoit, Nadia Berhoune, Sandra Felix, Maud Esteban-Mader, Igor Sibon, Annabelle Kazadi, François Rouanet, Pauline Renou, Sabrina Debruxelles, Mathilde Poli, Sharmila Sagnier, Jean-Louis Mas, Valérie Domigo, Catherine Lamy, Eric Bodiguel, Jérôme Grimaud, Valentin Bohotin, Michael Obadia, Candice Sabben, Erwan Morvan, Gilles Rodier, Wilfried Vadot, Hilde Hénon, Charlotte Cordonnier, Frédéric Dumont, Marie Bodenant, Christian Lucas, Solène Moulin, Nelly Dequatre, Sonia Alamowitch, Jean-Paul Muresan, Thomas Drouet, Magalie Gallea, Marie-Amélie Dalloz, Stephen Delorme, Marion Yger, Yannick Béjot, Philippe Loisel, Carine Bonnin, Virginie Bernigal, Guy Victor Osseby, Marie Hervieu-BègueMarsac, Pierre Garnier, Sandrine Accassat, Magali Epinat, Jérôme Varvat, Doïna Marinescu, Aude Triquenot-Bagan, Ozlem Ozkul-Wermester, Frédéric Philippeau, Angel Olaru, Anne Vieillart, Annie Lannuzel, Alice Demoly, Valérie Wolff, Mihaela Diaconu, Francisco Macian Montoro, Frédéric Faugeras, Laeticia Gimenez, Françoise Abdallah-Lebeau, Serge Timsit, Irina Viakhireva-Dovganyuk, Anne Tirel-Badets, François-Mathias Merrien, Philippe Goas, François Rouhart, Aurore Jourdain, Benoit Guillon, Fanny Hérissson, Mathieu Sevin-Allouet, Nathalie Nasr, Jean-Marc Olivot, Alderic Lecluse, Guillaume Marc, Emmanuel Touzé, Vincent de la Sayette, Marion Apoil, Li Lin, Julien Cogez, Sophie Guettier, Olivier Godefroy, Chantal Lamy, Jean-Marc Bugnicourt, Grégory Taurin, Marc Mérienne, Julien Gere, Anne-Marie Chessak, Tarik Habet, Anna Ferrier, Nathalie Bourgois, Dominique Minier, Marie Caillier-Minier, Fabienne Contégal-Callier, Philippe Vion, Yvan Vaschalde, Mohammed El Amrani, Mathieu Zuber, Marie Bruandet, Claire Join-Lambert, Pierre-Yves Garcia, Isabelle Serre, Jean-Marc Faucheux, Fatia Radji, Elena Leca-Radu, Thomas Debroucker, Rodica Cumurcuc, Serkan Cakmak, Stéphane Peysson, Emmanuel Ellie, Patricia Bernady, Thierry Moulin, Paola Montiel, Eugeniu Revenco, Pierre Decavel, Elisabeth Medeiros, Myriam Bouveret, Pierre Louchart, Claudia Vaduva, Grégory Couvreur, Eric Sartori, Adam Amer Alnajar-Carpentier, Michèle Levasseur, Pierre Louchart, Jean-Philippe Neau, Xavier Vandamme, Isabelle Meresse, Marc Bataillard, Canan Ozsancak, Katell Beauvais, Pascal Auzou, Joséphine Amevigbe, Francis Vuillemet, Marie-Hélène Dugay-Arentz, Gabriela Carelli, Mikel Martinez, Marcel Maillet-Vioud, Jean-Pierre Escaillas, Stéphane Chapuis, Jean Tardy, Eric Manchon, Olivier Varnet, Yong-Jae Kim, Yoonkyung Chang, Tae-Jin Song, Jong Sung Kim, Jung-Hoon Han, Kyung Chul Noh, Eun-Jae Lee, Dong-Wha Kang, Sun Uck Kwon, Boseoung Kwon, Seongho Park, Dongwhane Lee, Hyuk Sung Kwon, Daeun Jeong, MinHwan Lee, Joonggoo Kim, Hanbin Lee, Hyo Jung Nam, Sang Hun Lee, Bum Joon Kim, Jae-Kwan Cha, DaeHyun Kim, Rae Young Kim, Sang Wuk Sohn, Dong-Hyun Shim, Hyungjin Lee, Hyun-Wook Nah, Sang Min Sung, Kyung Bok Lee, Jeong Yoon Lee, Jee Eun Yoon, Eung-Gyu Kim, Jung Hwa Seo, Yong-Won Kim, Yangha Hwang, Man Seok Park, Joon-Tae Kim, Kang-Ho Choi, Hyo Suk Nam, Ji Hoe Heo, Young Dae Kim, In Gun Hwang, Hyung Jong Park, Kyoung Sub Kim, Jang Hyun Baek, Dong Beom Song, Joon Sang Yoo, Jong-Moo Park, Ohyun Kwon, Woong-Woo Lee, Jung-Ju Lee, Kyusik Kang, Byung Kun Kim, Jae-Sung Lim, Mi Sun Oh, Kyung-Ho Yu, Bora Hong, Mihoon Jang, Seyoung Jang, Jung Eun Jin, Jei Kim, Hye Seon Jeong, Keun Sik Hong, Hong Kyun Park, Yong Jin Cho, Oh Young Bang, Woo-Keun Seo, Jongwon Chung
- Subjects
Adult ,Male ,medicine.medical_specialty ,Statin ,medicine.drug_class ,[SDV]Life Sciences [q-bio] ,MEDLINE ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Brain Ischemia ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Text mining ,Pharmacotherapy ,Randomized controlled trial ,law ,Internal medicine ,Humans ,Medicine ,cardiovascular diseases ,030212 general & internal medicine ,Aged ,Intention-to-treat analysis ,business.industry ,Cholesterol ,Anticholesteremic Agents ,Cholesterol, LDL ,General Medicine ,Middle Aged ,Atherosclerosis ,Ezetimibe ,Intention to Treat Analysis ,Stroke ,chemistry ,Cardiovascular Diseases ,Ischemic Attack, Transient ,Ischemic stroke ,Drug Therapy, Combination ,Female ,lipids (amino acids, peptides, and proteins) ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
International audience; BACKGROUND: The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied. METHODS: In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3 months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.8 mmol per liter) (lower-target group) or to a target range of 90 mg to 110 mg per deciliter (2.3 to 2.8 mmol per liter) (higher-target group). All the patients had evidence of cerebrovascular or coronary-artery atherosclerosis and received a statin, ezetimibe, or both. The composite primary end point of major cardiovascular events included ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid revascularization, or death from cardiovascular causes. RESULTS: A total of 2860 patients were enrolled and followed for a median of 3.5 years; 1430 were assigned to each LDL cholesterol target group. The mean LDL cholesterol level at baseline was 135 mg per deciliter (3.5 mmol per liter), and the mean achieved LDL cholesterol level was 65 mg per deciliter (1.7 mmol per liter) in the lower-target group and 96 mg per deciliter (2.5 mmol per liter) in the higher-target group. The trial was stopped for administrative reasons after 277 of an anticipated 385 end-point events had occurred. The composite primary end point occurred in 121 patients (8.5%) in the lower-target group and in 156 (10.9%) in the higher-target group (adjusted hazard ratio, 0.78; 95% confidence interval, 0.61 to 0.98; P = 0.04). The incidence of intracranial hemorrhage and newly diagnosed diabetes did not differ significantly between the two groups. CONCLUSIONS: After an ischemic stroke or TIA with evidence of atherosclerosis, patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those who had a target range of 90 mg to 110 mg per deciliter. (Funded by the French Ministry of Health and others; Treat Stroke to Target ClinicalTrials.gov number, NCT01252875.).
- Published
- 2020
14. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke
- Author
-
Amarenco P, Kim J, Labreuche J, Charles H, Giroud M, Lee B, Mahagne M, Nighoghossian N, Steg P, Vicaut E, Bruckert E, and Treat Stroke Target Investigators
- Subjects
aorta ,cholesterol, LDL ,informed consent ,angiography ,stroke - Abstract
Background and Purpose-The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of 4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results in the French cohort. Methods-One thousand seventy-three French patients were assigned to
- Published
- 2020
15. Markers of endothelial damage are associated with successful recanalization in acute stroke: PB 2.74–6
- Author
-
Faille, D, Labreuche, J, Huisse, M G, Mazighi, M, and Ajzenberg, N
- Published
- 2013
16. Predictors of Favorable Outcome after Endovascular Thrombectomy in MRI: Selected Patients with Acute Basilar Artery Occlusion
- Author
-
Mahmoudi, M., primary, Dargazanli, C., additional, Cagnazzo, F., additional, Derraz, I., additional, Arquizan, C., additional, Wacogne, A., additional, Labreuche, J., additional, Bonafe, A., additional, Sablot, D., additional, Lefevre, P.H., additional, Gascou, G., additional, Gaillard, N., additional, Scott, C., additional, Costalat, V., additional, and Mourand, I., additional
- Published
- 2020
- Full Text
- View/download PDF
17. Endogenous tissue-type plasminogen activator and cardioembolic brain infarct subtype
- Author
-
OLIVOT, J. M., LABREUCHE, J., MAHAGNE, M. H., AIACH, M., and AMARENCO, P.
- Published
- 2006
18. 5 - Risk estimation of metastatic recurrence after prostatectomy: A model using preoperative MRI and targeted biopsy
- Author
-
Villers, A., Bommelaere, T., Puech, P., Ploussard, G., Labreuche, J., Leroy, X., and Olivier, J.
- Published
- 2022
- Full Text
- View/download PDF
19. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data
- Author
-
Louvet, A, Thursz, MR, Kim, DJ, Labreuche, J, Atkinson, S, Sidhu, SS, O'Grady, JG, Akriviadis, E, Sinakos, E, Carithers, RL, Ramond, M-J, Maddrey, WC, Morgan, TR, Duhamel, A, Mathurin, P, and Medical Research Council (MRC)
- Subjects
Science & Technology ,Time Factors ,Gastroenterology & Hepatology ,Survival ,Hepatitis, Alcoholic ,LONG-TERM ,Prednisolone ,alcoholic hepatitis ,1103 Clinical Sciences ,Survival Analysis ,THERAPY ,Severity of Illness Index ,meta-analysis ,Placebos ,SHORT-TERM SURVIVAL ,Treatment Outcome ,1114 Paediatrics and Reproductive Medicine ,Humans ,Drug Therapy, Combination ,Pentoxifylline ,1109 Neurosciences ,Life Sciences & Biomedicine ,Glucocorticoids ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND & AIMS: We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response to treatment based on the Lille model. METHODS: We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis. Our final analysis comprised 11 studies, of 2111 patients. We performed four meta-analyses of the effects of corticosteroids vs. placebo or control, corticosteroids vs. pentoxifylline, corticosteroids and pentoxifylline vs. corticosteroids and placebo or control, and pentoxifylline vs. placebo. In each meta-analysis, the effect of treatment on the primary outcome (overall survival at 28 days, defined as the period from the first day of assigned treatment to 28 days) was estimated using a Cox proportional hazards regression model, stratified by trial. RESULTS: Corticosteroid treatment significantly decreased risk of death within 28 days compared to controls (hazard ratio [HR], 0.64; 95% CI, 0.48-0.86) or to pentoxifylline (HR, 0.64; 95% CI, 0.43-0.95). In multiple imputation and complete case analyses, the effect of corticosteroids compared to controls remained significant. When we compared corticosteroids vs. pentoxifylline, the corticosteroid effect remained significant in the complete case analysis (HR, 0.66; P=.04) but not in multiple-imputation analysis (HR, 0.71; P=.08). There was no difference in 28-day mortality when patients were given a combination of corticosteroids and pentoxifylline vs. corticosteroids alone or between patients given pentoxifylline vs. control. In our analysis of secondary outcomes, we found no significant differences in 6-month mortality when any treatments or controls were compared. Corticosteroids were significantly associated with increased response to therapy compared with controls (relative risk, 1.24; 95% CI, 1.10-1.41) or pentoxifylline (relative risk, 1.43; 95% CI, 1.20-1.68). We found no difference in response to therapy between patients given a combination of corticosteroids and pentoxifylline vs. corticosteroids alone or pentoxifylline vs. controls. CONCLUSIONS: In a meta-analysis of 4 controlled trials, we found corticosteroid use to reduce risk of death within 28 days of treatment, but not in the following 6 months. This loss of efficacy over time indicates a need for new therapeutic strategies to improve medium-term outcomes.
- Published
- 2018
20. First-Line Sofia Aspiration Thrombectomy Approach within the Endovascular Treatment of Ischemic Stroke Multicentric Registry: Efficacy, Safety, and Predictive Factors of Success
- Author
-
Marnat, G., primary, Barreau, X., additional, Detraz, L., additional, Bourcier, R., additional, Gory, B., additional, Sgreccia, A., additional, Gariel, F., additional, Berge, J., additional, Menegon, P., additional, Kyheng, M., additional, Labreuche, J., additional, Consoli, A., additional, Blanc, R., additional, and Lapergue, B., additional
- Published
- 2019
- Full Text
- View/download PDF
21. MRI Quantitative T2* Mapping to Predict Dominant Composition of In Vitro Thrombus
- Author
-
Bourcier, R., primary, Pautre, R., additional, Mirza, M., additional, Castets, C., additional, Darcourt, J., additional, Labreuche, J., additional, Detraz, L., additional, Desal, H., additional, Serfaty, J.-M., additional, and Toquet, C., additional
- Published
- 2019
- Full Text
- View/download PDF
22. Clot Burden Score and Collateral Status and Their Impact on Functional Outcome in Acute Ischemic Stroke.
- Author
-
Derraz, I., Pou, M., Labreuche, J., Legrand, L, Soize, S., Tisserand, M., Rosso, C., Piotin, M., Boulouis, G., Oppenheim, C., Naggara, O., Bracard, S., Clarençon, F., Lapergue, B., and Bourcie, R.
- Published
- 2021
- Full Text
- View/download PDF
23. Supplementary Material for: Is Reperfusion Useful in Ischaemic Stroke Patients Presenting with a Low National Institutes of Health Stroke Scale and a Proximal Large Vessel Occlusion of the Anterior Circulation?
- Author
-
Dargazanli, C., Consoli, A., Gory, B., Blanc, R., Labreuche, J., Preda, C., Bourdain, F., Decroix, J.-P., Redjem, H., Ciccio, G., Mazighi, M., Smajda, S., Desilles, J.-P., Riva, R., Labeyrie, P.-E., Coskun, O., Rodesch, G., Turjman, F., Piotin, M., and Lapergue, B.
- Abstract
Background: In population-based studies, patients presenting with minor or mild stroke symptoms represent about two-thirds of stroke patients, and almost one-third of these patients are unable to ambulate independently at the time of discharge. Although mechanical thrombectomy (MT) has become the standard of care for acute ischaemic stroke with proximal large vessel occlusion (LVO) in the anterior circulation, the management of patients harbouring proximal occlusion and minor-to-mild stroke symptoms has not yet been determined by recent trials. The purpose of this study was to evaluate the impact of reperfusion on clinical outcome in low National Institutes of Health Stroke Scale (NIHSS) patients treated with MT. Methods: We analysed 138 consecutive patients with acute LVO of the anterior circulation (middle cerebral artery M1 or M2 segment, internal carotid artery or tandem occlusion) with NIHSS Results: Successful reperfusion was achieved in 81.2% of patients (TICI 2B, n = 47; TICI 3, n = 65). Excellent outcome (mRs 0-1) was achieved in 69 patients (65.0%) and favourable outcome (mRs ≤2) in 108 (78.3%). Death occurred in 7 (5.1%). Excellent outcome increased with reperfusion grades, with a rate of 34.6% in patients with failed/poor reperfusion, 61.7% in patients with TICI 2B reperfusion, and 78.5% in patients with TICI 3 reperfusion (p < 0.001). In multivariate analysis adjusted for patient characteristics associated with excellent outcome, the reperfusion grade remained significantly associated with an increase in excellent outcome; the OR (95% CI) was 3.09 (1.06-9.03) for TICI 2B and 6.66 (2.27-19.48) for TICI 3, using the failed/poor reperfusion grade as reference. Similar results were found regarding favourable outcome (90-day mRs 0-2) or overall mRS distribution (shift analysis). Conclusion: Successful reperfusion is strongly associated with better functional outcome among patients with proximal LVO in the anterior circulation and minor-to-mild stroke symptoms. Randomized controlled studies are mandatory to assess the benefit of MT compared with optimal medical management in this subset of patients.
- Published
- 2017
- Full Text
- View/download PDF
24. Tester une innovation technique favorable aux abeilles mellifères par des approches participative et expérimentale – Projet InterAPI 1
- Author
-
Fabrice Allier, Cedric Alaux, Pierrick Aupinel, Baechler, F., Baron, S., Bezine, M., Boone, V., Cervek, C., Coffion, R., Florent Decugis, Axel Decourtye, Delestra, E., Michel Etienne, Franck, R., Gratadou, P., Gourrat, M., Mickaël Henry, Labreuche, J., Le Bivic, P., Yves Le Conte, Lemeur, E., Lieven, J., Jean Francois Odoux, Remond, P., Thierry Tamic, Tosser, V., Vidau, C., Institut Technique et Scientifique de l'Apiculture et de la Pollinisation (ITSAP-Institut de l'Abeille), Abeilles et Environnement (AE), Institut National de la Recherche Agronomique (INRA)-Avignon Université (AU), UMT PrADE, Entomologie (ENTOMOLOGIE), Institut National de la Recherche Agronomique (INRA), Chambre d'Agriculture du Loir et Cher (CA 41), Chambre d'Agriculture du Loiret, Chambre d'Agriculture d'Eure et Loir (CA 28), Coop de France Centre, Chambre Régionale d'Agriculture du Centre, ACTA Informatique, Association de Coordination Technique Agricole (ACTA), Cité de l'Agriculture, Association de Développement de l'Apiculture du Centre, Unité de recherche d'Écodéveloppement (ECODEVELOPPEMENT), Jouffray-Drillaud, ARVALIS - Institut du végétal [Paris], Terres Inovia, Lycée d'Enseignement Général et Technologique Agricole La Saussaye - Chartres (LEGTA La Saussaye - Chartres), and Projet InterAPI 1
- Subjects
co-construction ,accompagnement des acteurs ,innovation technique ,culture intermédiaire mellifère ,Abeille mellifère ,technical innovation ,melliferous catch crops ,honey bee ,[SDV]Life Sciences [q-bio] - Abstract
La combinaison de la mortalité et de colonies non productrices en sortie d’hiver est responsable d’un taux de mortalité représentant près d’un tiers du cheptel. Nous nous sommes intéressés aux conditions environnementales des colonies d’abeilles mellifères à cette période cruciale de pré-hivernage. Une solution technique spécifique a été testée pour étudier l’influence de l’environnement sur la période d’hivernage des colonies. C’est grâce à une double approche d’accompagnement des acteurs et expérimentale s’appuyant sur une implication forte des agriculteurs et apiculteurs de la Beauce, que les partenaires du projet InterAPI mettent en évidence l’intérêt d’un aménagement du territoire qui intègre des cultures intermédiaires mellifères (CIM) favorables aux colonies. Ils identifient les espèces candidates et leurs caractéristiques grâce à deux outils d’aide à la gestion de cette interculture., The rates of honeybee colony winter losses remain very high describing mortalities and non-producing colonies after wintering represents nearly a third of the producing colonies. We were interested in environmental conditions of honeybee colonies at this crucial time. A technical solution has been tested and specifically to study environment influence on the wintering period of the colonies. Through a dual approach of co-construction and experimental, based on a strong involvement of farmers and beekeepers in Beauce region, partners of InterAPI project highlight the interest of a landscape management which includes melliferous catch crops. They identify candidate species and their characteristics using two tools helping the management of catch crops.
- Published
- 2017
25. Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org
- Author
-
Hoshino, T, Uchiyama, S, Wong, LKS, Sissani, L, Albers, GW, Bornstein, NM, Caplan, LR, Donnan, GA, Ferro, JM, Hennerici, MG, Labreuche, J, Lavallée, PC, Molina, C, Rothwell, PM, Steg, PG, Touboul, P-J, Vicaut, É, Amarenco, P, and Investigators, Tiaregistry.Org
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Internationality ,Population ,030204 cardiovascular system & hematology ,Lower risk ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Prospective Studies ,Registries ,Prospective cohort study ,education ,Stroke ,Aged ,Advanced and Specialized Nursing ,Aged, 80 and over ,education.field_of_study ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Confidence interval ,3. Good health ,Surgery ,Stenosis ,Treatment Outcome ,Ischemic Attack, Transient ,Female ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Background and Purpose— This study provides the contemporary causes and prognosis of transient ischemic attack (TIA) and minor stroke in Asians and the direct comparisons with non-Asians. Methods— The TIAregistry.org enrolled 4789 patients (1149 Asians and 3640 non-Asians) with a TIA or minor ischemic stroke within 7 days of onset. Every participating facility had systems dedicated to urgent intervention of TIA/stroke patients by specialists. The primary outcome was a composite of cardiovascular death, nonfatal stroke, and nonfatal acute coronary syndrome. Results— Approximately 80% of patients were evaluated within 24 hours of symptom onset. At 1 year, there were no differences in the rates of composite cardiovascular events (6.8% versus 6.0%; P =0.38) and stroke (6.0% versus 4.8%; P =0.11) between Asians and non-Asians. Asians had a lower risk of cerebrovascular disease (stroke or TIA) than non-Asians (adjusted hazard ratio, 0.79; 95% confidence interval, 0.63–0.98; P =0.03); the difference was primarily driven by a lower rate of TIA in Asians (4.2% versus 8.3%; P P =0.02). In multivariable analysis, multiple acute infarcts ( P =0.005) and alcohol consumption ( P =0.02) were independent predictors of stroke recurrence in Asians, whereas intracranial stenosis ( P 2 score ( P P =0.008), extracranial stenosis ( P =0.03), and previous stroke or TIA ( P =0.03) were independent predictors in non-Asians. Conclusions— The short-term stroke risk after a TIA or minor stroke was lower than expected when urgent evidence-based care was delivered, irrespective of race/ethnicity or region. However, the predictors of stroke were different for Asians and non-Asians.
- Published
- 2017
- Full Text
- View/download PDF
26. Supplementary Material for: Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries
- Author
-
Abboud, H., Sissani, L., Labreuche, J., Arauz, A., Bousser, M.-G., Bryer, A., Chamorro, A., Fisher, M., Ford, I., Fox, K.M., Hennerici, M.G., Lavados, P.M., Massaro, A., Mattle, H.P., Munoz Collazos, M., Rothwell, P.M., Steg, P.G., Vicaut, E., Yamouth, B., Amarenco, P., and Registry, On Behalf Of The OPTIC
- Abstract
Background: Stroke is largely preventable, and therefore, a better understanding of risk factors is an essential step in reducing the population stroke rate and resulting disease burden in Arab countries. Summary: We performed 2 separate analyses in 2 similar populations of patients with noncardioembolic ischemic stroke. This first involved 3,635 patients in the Outcomes in Patients with TIA and Cerebrovascular disease (OPTIC) registry (followed for 2 years), with baseline collection of the usual risk factors and 5 socioeconomic variables (unemployment status, residence in rural area, living in fully serviced accommodation, no health-insurance coverage, and low educational level). The second involved patients in the PERFORM trial (n = 19,100 followed up for 2 years), with baseline collection of the usual risk factors and 1 socioeconomic variable (low educational level). The primary outcome was a composite of nonfatal stroke, nonfatal myocardial infarction, or cardiovascular death. Stroke risk factors were more prevalent in patients in Arab countries. The incidence of major cardiovascular events (MACE; age- and gender-adjusted) was higher in Arab countries (OPTIC, 18.5 vs. 13.3%; PERFORM, 18.4 vs. 9.7%; both p ≤ 0.0001). These results remained significant after adjustment on risk factors and were attenuated in OPTIC after further adjustment on socioeconomic variables (hazard ratio 1.24; 95% CI 0.98-1.55; p = 0.07). Key Messages: Patients with ischemic stroke living in Arab countries had a lower mean socioeconomic status, a much higher prevalence of diabetes mellitus, and a higher rate of MACE compared with patients from non-Arab countries. This finding is partly explained by a higher prevalence of risk factors and also by a high prevalence of poverty and low educational level.
- Published
- 2017
- Full Text
- View/download PDF
27. ASSESSING RISK OVER TIME IN PATIENTS WITH SYMPTOMATIC WALDENSTROM MACROGLOBULINEMIA (WM). A STUDY ON 114 PATIENTS (PTS)
- Author
-
Guidez, S., Labreuche, J., Bakala, J., Royer, B., Delette, C., Joris, M., Hivert, B., Declercq, H., Verlay, M., Marolleau, Jean-Pierre, Duhamel, A., Morel, P., DESSAIVRE, Louise, Centre hospitalier universitaire de Poitiers (CHU Poitiers), ARVALIS - Institut du végétal [Paris], Institut de Chimie des Substances Naturelles (ICSN), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Etablissement français du sang [Poitiers] (EFS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Site de Recherche Intégrée en Cancérologie (SIRIC-ONCOLille), Université de Lille, Sciences et Technologies-Université de Lille, Sciences Humaines et Sociales-Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), and Université de Lille-UNICANCER-Université de Lille-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,parasitic diseases ,education ,social sciences ,health care economics and organizations ,geographic locations - Abstract
22nd Congress of the European-Hematology-Association, Madrid, SPAIN, JUN 22-25, 2017; International audience
- Published
- 2017
28. The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment
- Author
-
Amarenco, P, Sissani, L, Labreuche, J, Vicaut, E, Bousser, MG, Chamorro, A, Fisher, M, Ford, I, Fox, KM, Hennerici, MG, Mattle, H, Rothwell, PM, Steg, PG, Diener, H-C, Sacco, RL, Greving, JP, and Algra, A
- Subjects
Male ,PARALLEL-GROUP ,Time Factors ,RECURRENT STROKE ,Clinical Neurology ,Lacune ,Kaplan-Meier Estimate ,CONTROLLED-TRIAL ,Risk Assessment ,ATTACK PERFORM ,Disease-Free Survival ,Brain Ischemia ,DOUBLE-BLIND ,Elderly ,Risk Factors ,Journal Article ,Humans ,cardiovascular diseases ,EXTENDED-RELEASE DIPYRIDAMOLE ,CARDIOVASCULAR EVENTS ,Cerebrovascular disease ,PERFORM and PRoFESS Committees and Investigators ,Aged ,Proportional Hazards Models ,Science & Technology ,CEREBRAL MICROBLEEDS ,Neurology & Neurosurgery ,ACUTE CORONARY SYNDROMES ,Low body mass index ,1103 Clinical Sciences ,Middle Aged ,Cardiovascular disease ,PROGNOSTIC MODEL ,Stroke ,Treatment Outcome ,Peripheral Vascular Disease ,Multivariate Analysis ,Cardiovascular System & Cardiology ,Blood pressure ,Dual antithrombotic treatment or anticoagulant ,Linear Models ,Asian ethnicity ,Sex ,Female ,Neurosciences & Neurology ,1109 Neurosciences ,Life Sciences & Biomedicine ,Intracranial Hemorrhages ,Platelet Aggregation Inhibitors - Abstract
BACKGROUND Chronic antiplatelet therapy in the post-acute phase of non-cardioembolic ischemic stroke is limited by the risk of intracranial hemorrhage (ICH) complications. METHODS We developed an ICH risk score based on the PERFORM trial cohort (n = 19,100), which included patients with a non-cardioembolic ischemic stroke or transient ischemic attack, and externally validated this score in one contemporary trial of very similar size and inclusion criteria, the PRoFESS trial (n = 20,332 patients). Outcome was ICH over 2 years. A Cox proportional-hazard regression analysis identified risk factors. Discrimination was quantified with c-statistics and calibration was assessed by comparing predicted and observed ICH risk in PERFORM and PRoFESS. RESULTS ICH occurred within 2 years in 263 (1.4%) patients in PERFORM trial and in 246 (1.2%) patients in PRoFESS trial. A 13-point score based on 9 items (Intracranial-B2LEED3S score - low body mass index, blood pressure, lacune, elderly, Asian ethnicity, coronary artery or cerebrovascular disease history, dual antithrombotic agent or oral anticoagulant, gender) was derived from the PERFORM trial. In PERFORM, the observed 2-year ICH risk varied from 0.75% in low-risk (score ≤2) to 2.44% in high-risk patients (score ≥5) with an acceptable calibration but a low discrimination both in PERFORM (c-statistic 0.64, 95% CI 0.61-0.68) and on external validation in PRoFESS (0.58, 95% CI 0.55-0.62). CONCLUSION The Intracranial-B2LEED3S score helps identify patients who are at a high risk of bleeding. However, other variables need to be identified to improve the score (e.g., microbleeds) (Clinical Trial Registration Information ISRCTN66157730). URL: http://www.isrctn.com/ISRCTN66157730?totalResults=5&pageSize=10&page=1&searchType=basic-search&offset=3&q=&filters=conditionCategory%3ACirculatory+System%2CrecruitmentCountry%3ATaiwan%2CrecruitmentCountry%3AAustria&sort=.
- Published
- 2017
- Full Text
- View/download PDF
29. MA 03.10 Prognostic Factors in NSCLC Patients Treated with a Fourth-Line Therapy
- Author
-
Leroy, V., primary, Labreuche, J., additional, Gey, T., additional, Terce, G., additional, Willemin, M.C., additional, Dhalluin, X., additional, Wasielewski, E., additional, Scherpereel, A., additional, and Cortot, A., additional
- Published
- 2017
- Full Text
- View/download PDF
30. Abstracts from the Food Allergy and Anaphylaxis Meeting 2016
- Author
-
Pouessel, G, Claverie, C, Labreuche, J, Renaudin, J-M, Dorkenoo, A, Eb, M, Moneret-Vautrin, A, Deschildre, A, Leteurtre, S, Grabenhenrich, L, Worm, M, Dölle, S, Scherer, K, Hutteger, I, Christensen, M, Bindslev-Jensen, C, Mortz, C, Eller, E, Kjaer, HF, Carneiro-Leão, L, Badas, J, Coimbra, A, Levy, DP, Ben-Shoshan, M, Rimon, A, Benor, S, Arends, NJT, Edelbroek, N, de Groot, H, Emons, JAM, Brand, HKA, Verhoeven, D, van Veen, LN, de Jong, NW, Noh, G, Jang, EH, Pascal, M, Dominguez, O, Piquer, M, Alvaro, M, Jimenez-Feijoo, R, Lozano, J, Machinena, A, del Mar Folqué, M, Giner, MT, Plaza, AM, Turner, P, Patel, N, Vazquez-Ortiz, M, Lindsley, S, Walker, L, Rosenberg, S, Mari, A, Alessandri, C, Giangrieco, I, Tuppo, L, Rafaiani, C, Mitterer, G, Ciancamerla, M, Ferrara, R, Bernardi, ML, Zennaro, D, Tamburrini, M, Ciardiello, MA, Harwanegg, C, Fernandez, A, Selb, R, Egenmann, P, Epstein, M, Hoffmann-Sommergruber, K, Koning, F, Lovik, M, Clare Mills, EN, Moreno, J, van Loveren, H, Wal, J-M, Diesner, S, Bergmayr, C, Pfitzner, B, Assmann, VE, Starkl, P, Endesfelder, D, Eiwegger, T, Szepfalusi, Z, Fehrenbach, H, Jensen-Jarolim, E, Hartmann, A, Pali-Schöll, I, Untersmayr, E, Wille, S, Meyer, P, Klingebiel, C, Lidholm, J, Ehrenberg, A, Östling, J, Cleach, I, Mège, J-L, Vitte, J, Aina, R, Dubiela, P, Pfeifer, S, Bublin, M, Radauer, C, Humeniuk, P, Kabasser, S, Asero, R, Bogas, G, Gomez, F, Campo, P, Salas, M, Doña, I, Barrionuevo, E, Guerrero, MA, Mayorga, C, Prieto, A, Barber, D, Torres, MJ, Jamin, A, Wangorsch, A, Ballmer, B, Vieths, S, Scheurer, S, Apostolovic, D, Mihailovic, J, Krstic, M, Starkhammar, M, Velickovic, TC, Hamsten, C, van Hage, M, van Erp, FC, Knol, EF, Kansen, HM, Pontoppidan, B, Meijer, Y, van der Ent, CK, Knulst, AC, Sayers, R, Brown, H, Custovic, A, Simpson, A, Mills, C, Schulz, J, Akkerdaas, J, Totis, M, Capt, A, Herouet-Guicheney, C, van Ree, R, Banerjee, T, Banerjee, A, Claude, M, Bouchaud, G, Lupi, R, Castan, L, Tranquet, O, Denery-Papini, S, Bodinier, M, Brossard, C, De Poi, R, Gritti, E, De Dominicis, E, Popping, B, de Laureto, PP, Palosuo, K, Kukkonen, AK, Pelkonen, A, Mäkelä, M, Lee, NA, Rost, J, Muralidharan, S, Campbell, D, Mehr, S, Nock, C, Baumert, J, Taylor, S, Mastrorilli, C, Tripodi, S, Caffarelli, C, Perna, S, Di Rienzo Businco, A, Sfika, I, Dondi, A, Bianchi, A, Dascola, CP, Ricci, G, Cipriani, F, Maiello, N, del Giudice, MM, Frediani, T, Frediani, S, Macrì, F, Pistoletti, C, Iacono, ID, Patria, MF, Varin, E, Peroni, D, Comberiati, P, Chini, L, Moschese, V, Lucarelli, S, Bernardini, R, Pingitore, G, Pelosi, U, Olcese, R, Moretti, M, Cirisano, A, Faggian, D, Travaglini, A, Plebani, M, Verga, MC, Calvani, M, Giordani, P, Matricardi, PM, Ontiveros, N, Cabrera-Chavez, F, Galand, J, Beaudouin, E, Pineau, F, Sakai, S, Matsunaga, K, Teshima, R, Larré, C, Denery, S, Tschirner, S, Trendelenburg, V, Schulz, G, Niggemann, B, Beyer, K, Bouferkas, Y, Belabbas, Y, Saidi, D, Kheroua, O, Mecherfi, KEE, Guendouz, M, Haddi, A, Kaddouri, H, Amaral, L, Pereira, A, Rodrigues, S, Datema, M, Jongejan, L, Clausen, M, Knulst, A, Papadopoulos, N, Kowalski, M, de Blay, F, Zwinderman, A, Hoffman-Sommergruber, K, Ballmer-Weber, B, Fernandez-Rivas, M, Deng, S, Yin, J, Eisenmann, C, Nassiri, M, Reinert, R, van der Valk, JPM, van Wijk, RG, Vergouwe, Y, Steyerberg, EW, Reitsma, M, Wichers, HJ, Savelkoul, HFJ, Vlieg-Boerstra, B, Dubois, AEJ, Carolino, F, Rodolfo, A, Cernadas, J, Roa-Medellín, D, Rodriguez-Fernandez, A, Navarro, J, Albendiz, V, Baeza, ML, Intente-Herrero, S, Mikkelsen, A, Mehlig, K, Lissner, L, Verrill, L, Luccioli, S, van Bilsen, J, Kuper, F, Wolterbeek, A, Rankouhi, TR, Verschuren, L, Cnossen, H, Jeurink, P, Garssen, J, Knippels, L, Garthoff, J, Houben, G, Leeman, W, Eleonore Pettersson, M, Schins, AMM, Koppelman, GH, Kollen, BJ, Zubchenko, S, Kuntz, S, Mérida, P, Álvaro, M, Riggioni, C, Castellanos, JH, Jimenez, R, Cap, M, Drumez, E, Lejeune, S, Thumerelle, C, Mordacq, C, Nève, V, Ricò, S, Varini, M, Nocerino, R, Cosenza, L, Amoroso, A, Di Costanzo, M, Di Scala, C, Bedogni, G, Canani, RB, Turner, PJ, Poza-Guedes, P, González-Pérez, R, Sánchez-Machín, I, Matheu-Delgado, V, Wambre, E, Ballegaard, A-S, Madsen, C, Gregersen, J, Bøgh, KL, Aubert, P, Neunlist, M, Magnan, A, Lozano-Ojalvo, D, Pablos-Tanarro, A, Pérez-Rodríguez, L, Molina, E, López-Fandiño, R, Rekima, A, Macchiaverni, P, Turfkruyer, M, Holvoet, S, Dupuis, L, Baiz, N, Annesi-Maesano, I, Mercenier, A, Nutten, S, Verhasselt, V, Mrakovcic-Sutic, I, Banac, S, Sutic, I, Baricev-Novakovic, Z, Pavisic, V, Muñoz-Cano, R, Jiménez-Rodríguez, T, Corbacho, D, Roca-Ferrer, J, Bartra, J, Bulog, A, Micovic, V, Markiewicz, L, Szymkiewicz, A, Szyc, A, Wróblewska, B, Harvey, BM, Harthoorn, LF, Wesley Burks, A, Rentzos, G, Björk, A-LB, Bengtsson, U, Barber, C, Kalicinsky, C, Breynaert, C, Coorevits, L, Jansen, C, Van Hoeyveld, E, Verbeke, K, Kochuyt, A-M, Schrijvers, R, Deleanu, D, Muntean, A, Konstantakopoulou, M, Pasioti, M, Papadopoulou, A, Iliopoulou, A, Mikos, N, Kompoti, E, de Castro, ED, Bartalomé, B, Ue, KL, Griffiths, E, Till, S, Grimshaw, K, Roberts, G, Selby, A, Butiene, I, Larco, JI, Dubakiene, R, Fiandor, A, Fiocchi, A, Sigurdardottir, S, Sprikkelman, A, Schoemaker, A-F, Xepapadaki, P, Keil, T, Cojocariu, Z, Barbado, BS, Iancu, V, Arroabarren, E, Esarte, MG, Arteaga, M, Andrade, MC, Borges, D, Kalil, J, Bianchi, PG, Agondi, RC, Gupta, RK, Sharma, A, Gupta, K, Das, M, Dwivedi, P, Karseladze, R, Jorjoliani, L, Saginadze, L, Tskhakaia, M, Basello, K, Piuri, G, Speciani, AF, Speciani, MC, Camerotto, C, Zinno, F, Pakholchuk, O, Nedelska, S, Pattini, S, Costantino, MT, Peveri, S, Villalta, D, Savi, E, Costanzi, A, Revyakina, VA, Kiseleva, MA, Kuvshinova, ED, Larkova, IA, Shekhetov, AA, Silva, D, Moreira, A, Plácido, J, van der Kleij, H, van Twuijver, E, Sutorius, R, de Kam, P-J, van Odijk, J, Lindqvist, H, Lustig, E, Jácome, AAA, Aguilar, KLB, Domínguez, MG, Hernández, DAM, Caruso, C, Casale, C, Rapaccini, GL, Romano, A, De Vitis, I, Cocco, RR, Aranda, C, Mallozi, MC, Motta, JF, Moraes, L, Pastorino, A, Rosario, N, Goudouris, E, Porto, A, Wandalsen, NF, Sarinho, E, Sano, F, Solé, D, Pitsios, C, Petrodimopoulou, M, Papadopoulou, E, Passioti, M, Kontogianni, M, Adamia, N, Khaleva, E, del Prado, AP, Du Toit, G, Krzych, E, Samolinska-Zawisza, U, Furmanczyk, K, Tomaszewska, A, Raciborski, F, Lipiec, A, Samel-Kowalik, P, Walkiewicz, A, Borowicz, J, Samolinski, B, Nano, AL, Recto, M, Somoza, ML, López, NB, Alzate, DP, Ruano, FJ, Garcimartín, MI, Haroun, E, de la Torre, MV, Rojas, A, Onieva, ML, Canto, G, Rodrigues, A, Forno, A, Cabral, AJ, Gonçalves, R, Vorozhko, I, Sentsova, T, Chernyak, O, Denisova, S, Ilènko, L, Muhortnich, V, Zimmermann, C, Rohrbach, A, Bakhsh, FR, Boudewijn, K, Oomkes-Pilon, A-M, Van Ginkle, D, Šilar, M, Jeverica, A, Vesel, T, Avčin, T, Korošec, P, van der Valk, J, Berends, I, Arends, N, van Maaren, M, Wichers, H, Emons, J, Dubois, A, de Jong, N, Matsyura, O, Besh, L, Huang, C-H, Jan, T-R, Stiefel, G, Tratt, J, Kirk, K, Arasi, S, Caminiti, L, Crisafulli, G, Fiamingo, C, Fresta, J, Pajno, G, Remington, B, Kruizinga, A, Marty Blom, W, Westerhout, J, Bijlsma, S, Blankestijn, M, Otten, H, Klemans, R, Michelsen-Huisman, AD, van Os-Medendorp, H, Kruizinga, AG, Versluis, A, van Duijn, G, de Zeeuw-Brouwer, HM-L, Castenmiller, JJM, Noteborn, HPJM, Houben, GF, Bravin, K, Luyt, D, Javed, B, Couch, P, Munro, C, Padfield, P, Sperrin, M, Byrne, A, Oosthuizen, L, Kelleher, C, Ward, F, Brosnan, N, King, G, Corbet, E, Guzmán, JAH, García, MB, Asensio, O, Navarrete, LV, Larramona, H, Miró, XD, Pyrz, K, Austin, M, Boloh, Y, Galloway, D, Hernandez, P, Hourihane, JOB, Kenna, F, Majkowska-Wojciechowska, B, Regent, L, Themisb, M, Schnadt, S, Semic-Jusufagic, A, Galvin, AD, Kauppila, T, Kuitunen, M, Kitsioulis, NA, Douladiris, N, Kostoudi, S, Manolaraki, I, Mitsias, D, Manousakis, E, Papadopoulos, NG, Knibb, R, Hammond, J, Cooke, R, Yrjänä, J, Hanni, A-M, Vähäsarja, P, Mustonen, O, Dunder, T, Kulmala, P, Lasa, E, D’Amelio, C, Martínez, S, Joral, A, Gastaminza, G, Goikoetxea, MJ, Candy, DCA, Van Ampting, MTJ, Oude Nijhuis, MM, Butt, AM, Peroni, DG, Fox, AT, Knol, J, Michaelis, LJ, Padua, I, Padrao, P, Moreira, P, Barros, R, Sharif, H, Ahmed, M, Gomaa, N, Mens, J, Smit, K, Timmermans, F, Poredoš, T, Jeverica, AK, Sedmak, M, Benedik, E, Accetto, M, Zupančič, M, Yonamine, G, Soldateli, G, Aquilante, B, Pastorino, AC, de Moraes Beck, CL, Gushken, AK, de Barros Dorna, M, dos Santos, CN, Castro, APM, Al-Qahtani, A, Arnaout, R, Khaliq, AR, Amin, R, Sheikh, F, Alvarez, J, Anda, M, Palacios, M, De Prada, M, Ponce, C, Balbino, B, Sibilano, R, Marichal, T, Gaudenzio, N, Karasuyama, H, Bruhns, P, Tsai, M, Reber, LL, Galli, SJ, Ferreira, AR, Cernadas, JR, del Campo García, A, Fernández, SP, Carrera, NS, Sánchez-Cruz, FB, Lorenzo, JRF, Claus, S, Pföhler, C, Ruëff, F, Treudler, R, Jaume, ME, Madroñero, A, Perez, MTG, Julia, JC, Plovdiv, CH, Gethings, L, Langridge, J, Adel-Patient, K, Bernard, H, Barcievic-Jones, I, Sokolova, R, Yankova, R, Ivanovska, M, Murdjeva, M, Popova, T, Dermendzhiev, S, Karjalainen, M, Lehnigk, U, Brown, D, Locklear, JC, Locklear, J, Maris, I, Hourihane, J, Ornelas, C, Caiado, J, Ferreira, MB, Pereira-Barbosa, M, Puente, Y, Daza, JC, Monteseirin, FJ, Ukleja-Sokolowska, N, Gawronska-Ukleja, E, Zbikowska-Gotz, M, Bartuzi, Z, Sokolowski, L, Adams, A, Mahon, B, English, K, Gourdon-Dubois, N, Sellam, L, Pereira, B, Michaud, E, Messaoudi, K, Evrard, B, Fauquert, J-L, Palomares, F, Gomez, G, Rodriguez, MJ, Galindo, L, Molina, A, Paparo, L, Mennini, M, Aitoro, R, Wawrzeńczyk, A, Przybyszewski, M, Sarıcoban, HE, Ugras, M, Yalvac, Z, Flokstra-de Blok, BMJ, van der Velde, JL, Vereda, A, Ippolito, C, Traversa, A, Adriano, D, Bianchi, DM, Gallina, S, Decastelli, L, Makatsori, M, Miles, A, Devetak, SP, Devetak, I, Tabet, SA, Trandbohus, JF, Winther, P, Malling, H-J, Hansen, KS, Garvey, LH, Wang, C-C, Cheng, Y-H, Tung, C-W, Dietrich, M, Marenholz, I, Kalb, B, Grosche, S, Blümchen, K, Schlags, R, Price, M, Rietz, S, Esparza-Gordillo, J, Lau, S, Lee, Y-A, Almontasheri, A, Bahkali, MA, Elshorbagi, S, Alfhaid, A, Altamimi, M, Madbouly, E, Al-Dhekri, H, Arnaout, RK, Basagaña, M, Miquel, S, Bartolomé, B, Brix, B, Rohwer, S, Brandhoff, S, Berger, A, Suer, W, Weimann, A, Bueno, C, Martín-Pedraza, L, Abián, S, Segundo-Acosta, PS, López-Rodríguez, JC, Barderas, R, Batanero, E, Cuesta-Herranz, J, Villalba, MT, Correia, M, Benito-Garcia, F, Arêde, C, Piedade, S, Morais-Almeida, M, Hindley, J, Yarham, R, Kuklinska-Pijanka, A, Gillick, D, Patient, K, Chapman, MD, Miranda, A, Matos, E, Sokolova, A, Rao, H, Baricevic-Jones, I, Smith, F, Xue, W, Magnusdottir, H, Vidarsdottir, AG, Lund, S, Jensen, AB, Ludviksson, BR, Simon, R, Elfont, R, Bennett, S, Voyksner, R, de Lurdes Torre, M, Yürek, S, Faber, MA, Bastiaensen, A, Mangodt, E, van Gasse, A, Decuyper, I, Sabato, V, Hagendorens, MM, Bridts, CH, De Clerck, LS, Ebo, D, Schwarz, S, Ziegert, M, Albroscheit, S, Schwager, C, Kull, S, Behrends, J, Röckendorf, N, Schocker, F, Frey, A, Homann, A, Becker, W-M, Jappe, U, Zaabat, N, Osscini, S, Agabriel, C, Sterling, B, Carsin, A, Liabeuf, V, Maćków, M, Zbróg, A, Bronkowska, M, Courtois, J, Gadisseur, R, Bertholet, C, Lukas, P, Cavalier, E, Delahaut, P, Quinting, B, Gertmo, MB, Hasseus, ET, Barzylovych, V, Oliveira, J, Ensina, LF, Aranda, CS, Dopazo, L, Lopez, R, Perez, R, Santos-Diez, L, Bilbao, A, Garcia, JM, Núñez, IG, Mármol, MÁA, Villarejo, MJB, Martos, JAB, Vergara, MS, García, JMI, Michalska, A, Sergiejko, G, Zacniewski, R, Ghiordanescu, I-M, Deaconu, C, Popescu, M, Bumbacea, RS, Ibranji, A, Nikolla, E, Loloci, G, Juel-Berg, N, Larsen, LF, Poulsen, LK, Marcelino, J, Prata, R, Costa, AC, Duarte, F, Neto, M, Santos, J, Pestana, LC, Sampaio, D, Minale, P, Dignetti, P, Bignardi, D, Nedelea, I, Popescu, F-D, Vieru, M, Secureanu, F-A, Ganea, CS, Vieira, M, Silva, JPM, Watts, T, Watts, S, Lomikovska, M, Peredelskaya, M, Nenasheva, N, Filipovic, I, Zivkovic, Z, Filipovic, D, Higgs, J, Warner, A, Jones, C, Pouessel, G, Claverie, C, Labreuche, J, Renaudin, J-M, Dorkenoo, A, Eb, M, Moneret-Vautrin, A, Deschildre, A, Leteurtre, S, Grabenhenrich, L, Worm, M, Dölle, S, Scherer, K, Hutteger, I, Christensen, M, Bindslev-Jensen, C, Mortz, C, Eller, E, Kjaer, HF, Carneiro-Leão, L, Badas, J, Coimbra, A, Levy, DP, Ben-Shoshan, M, Rimon, A, Benor, S, Arends, NJT, Edelbroek, N, de Groot, H, Emons, JAM, Brand, HKA, Verhoeven, D, van Veen, LN, de Jong, NW, Noh, G, Jang, EH, Pascal, M, Dominguez, O, Piquer, M, Alvaro, M, Jimenez-Feijoo, R, Lozano, J, Machinena, A, del Mar Folqué, M, Giner, MT, Plaza, AM, Turner, P, Patel, N, Vazquez-Ortiz, M, Lindsley, S, Walker, L, Rosenberg, S, Mari, A, Alessandri, C, Giangrieco, I, Tuppo, L, Rafaiani, C, Mitterer, G, Ciancamerla, M, Ferrara, R, Bernardi, ML, Zennaro, D, Tamburrini, M, Ciardiello, MA, Harwanegg, C, Fernandez, A, Selb, R, Egenmann, P, Epstein, M, Hoffmann-Sommergruber, K, Koning, F, Lovik, M, Clare Mills, EN, Moreno, J, van Loveren, H, Wal, J-M, Diesner, S, Bergmayr, C, Pfitzner, B, Assmann, VE, Starkl, P, Endesfelder, D, Eiwegger, T, Szepfalusi, Z, Fehrenbach, H, Jensen-Jarolim, E, Hartmann, A, Pali-Schöll, I, Untersmayr, E, Wille, S, Meyer, P, Klingebiel, C, Lidholm, J, Ehrenberg, A, Östling, J, Cleach, I, Mège, J-L, Vitte, J, Aina, R, Dubiela, P, Pfeifer, S, Bublin, M, Radauer, C, Humeniuk, P, Kabasser, S, Asero, R, Bogas, G, Gomez, F, Campo, P, Salas, M, Doña, I, Barrionuevo, E, Guerrero, MA, Mayorga, C, Prieto, A, Barber, D, Torres, MJ, Jamin, A, Wangorsch, A, Ballmer, B, Vieths, S, Scheurer, S, Apostolovic, D, Mihailovic, J, Krstic, M, Starkhammar, M, Velickovic, TC, Hamsten, C, van Hage, M, van Erp, FC, Knol, EF, Kansen, HM, Pontoppidan, B, Meijer, Y, van der Ent, CK, Knulst, AC, Sayers, R, Brown, H, Custovic, A, Simpson, A, Mills, C, Schulz, J, Akkerdaas, J, Totis, M, Capt, A, Herouet-Guicheney, C, van Ree, R, Banerjee, T, Banerjee, A, Claude, M, Bouchaud, G, Lupi, R, Castan, L, Tranquet, O, Denery-Papini, S, Bodinier, M, Brossard, C, De Poi, R, Gritti, E, De Dominicis, E, Popping, B, de Laureto, PP, Palosuo, K, Kukkonen, AK, Pelkonen, A, Mäkelä, M, Lee, NA, Rost, J, Muralidharan, S, Campbell, D, Mehr, S, Nock, C, Baumert, J, Taylor, S, Mastrorilli, C, Tripodi, S, Caffarelli, C, Perna, S, Di Rienzo Businco, A, Sfika, I, Dondi, A, Bianchi, A, Dascola, CP, Ricci, G, Cipriani, F, Maiello, N, del Giudice, MM, Frediani, T, Frediani, S, Macrì, F, Pistoletti, C, Iacono, ID, Patria, MF, Varin, E, Peroni, D, Comberiati, P, Chini, L, Moschese, V, Lucarelli, S, Bernardini, R, Pingitore, G, Pelosi, U, Olcese, R, Moretti, M, Cirisano, A, Faggian, D, Travaglini, A, Plebani, M, Verga, MC, Calvani, M, Giordani, P, Matricardi, PM, Ontiveros, N, Cabrera-Chavez, F, Galand, J, Beaudouin, E, Pineau, F, Sakai, S, Matsunaga, K, Teshima, R, Larré, C, Denery, S, Tschirner, S, Trendelenburg, V, Schulz, G, Niggemann, B, Beyer, K, Bouferkas, Y, Belabbas, Y, Saidi, D, Kheroua, O, Mecherfi, KEE, Guendouz, M, Haddi, A, Kaddouri, H, Amaral, L, Pereira, A, Rodrigues, S, Datema, M, Jongejan, L, Clausen, M, Knulst, A, Papadopoulos, N, Kowalski, M, de Blay, F, Zwinderman, A, Hoffman-Sommergruber, K, Ballmer-Weber, B, Fernandez-Rivas, M, Deng, S, Yin, J, Eisenmann, C, Nassiri, M, Reinert, R, van der Valk, JPM, van Wijk, RG, Vergouwe, Y, Steyerberg, EW, Reitsma, M, Wichers, HJ, Savelkoul, HFJ, Vlieg-Boerstra, B, Dubois, AEJ, Carolino, F, Rodolfo, A, Cernadas, J, Roa-Medellín, D, Rodriguez-Fernandez, A, Navarro, J, Albendiz, V, Baeza, ML, Intente-Herrero, S, Mikkelsen, A, Mehlig, K, Lissner, L, Verrill, L, Luccioli, S, van Bilsen, J, Kuper, F, Wolterbeek, A, Rankouhi, TR, Verschuren, L, Cnossen, H, Jeurink, P, Garssen, J, Knippels, L, Garthoff, J, Houben, G, Leeman, W, Eleonore Pettersson, M, Schins, AMM, Koppelman, GH, Kollen, BJ, Zubchenko, S, Kuntz, S, Mérida, P, Álvaro, M, Riggioni, C, Castellanos, JH, Jimenez, R, Cap, M, Drumez, E, Lejeune, S, Thumerelle, C, Mordacq, C, Nève, V, Ricò, S, Varini, M, Nocerino, R, Cosenza, L, Amoroso, A, Di Costanzo, M, Di Scala, C, Bedogni, G, Canani, RB, Turner, PJ, Poza-Guedes, P, González-Pérez, R, Sánchez-Machín, I, Matheu-Delgado, V, Wambre, E, Ballegaard, A-S, Madsen, C, Gregersen, J, Bøgh, KL, Aubert, P, Neunlist, M, Magnan, A, Lozano-Ojalvo, D, Pablos-Tanarro, A, Pérez-Rodríguez, L, Molina, E, López-Fandiño, R, Rekima, A, Macchiaverni, P, Turfkruyer, M, Holvoet, S, Dupuis, L, Baiz, N, Annesi-Maesano, I, Mercenier, A, Nutten, S, Verhasselt, V, Mrakovcic-Sutic, I, Banac, S, Sutic, I, Baricev-Novakovic, Z, Pavisic, V, Muñoz-Cano, R, Jiménez-Rodríguez, T, Corbacho, D, Roca-Ferrer, J, Bartra, J, Bulog, A, Micovic, V, Markiewicz, L, Szymkiewicz, A, Szyc, A, Wróblewska, B, Harvey, BM, Harthoorn, LF, Wesley Burks, A, Rentzos, G, Björk, A-LB, Bengtsson, U, Barber, C, Kalicinsky, C, Breynaert, C, Coorevits, L, Jansen, C, Van Hoeyveld, E, Verbeke, K, Kochuyt, A-M, Schrijvers, R, Deleanu, D, Muntean, A, Konstantakopoulou, M, Pasioti, M, Papadopoulou, A, Iliopoulou, A, Mikos, N, Kompoti, E, de Castro, ED, Bartalomé, B, Ue, KL, Griffiths, E, Till, S, Grimshaw, K, Roberts, G, Selby, A, Butiene, I, Larco, JI, Dubakiene, R, Fiandor, A, Fiocchi, A, Sigurdardottir, S, Sprikkelman, A, Schoemaker, A-F, Xepapadaki, P, Keil, T, Cojocariu, Z, Barbado, BS, Iancu, V, Arroabarren, E, Esarte, MG, Arteaga, M, Andrade, MC, Borges, D, Kalil, J, Bianchi, PG, Agondi, RC, Gupta, RK, Sharma, A, Gupta, K, Das, M, Dwivedi, P, Karseladze, R, Jorjoliani, L, Saginadze, L, Tskhakaia, M, Basello, K, Piuri, G, Speciani, AF, Speciani, MC, Camerotto, C, Zinno, F, Pakholchuk, O, Nedelska, S, Pattini, S, Costantino, MT, Peveri, S, Villalta, D, Savi, E, Costanzi, A, Revyakina, VA, Kiseleva, MA, Kuvshinova, ED, Larkova, IA, Shekhetov, AA, Silva, D, Moreira, A, Plácido, J, van der Kleij, H, van Twuijver, E, Sutorius, R, de Kam, P-J, van Odijk, J, Lindqvist, H, Lustig, E, Jácome, AAA, Aguilar, KLB, Domínguez, MG, Hernández, DAM, Caruso, C, Casale, C, Rapaccini, GL, Romano, A, De Vitis, I, Cocco, RR, Aranda, C, Mallozi, MC, Motta, JF, Moraes, L, Pastorino, A, Rosario, N, Goudouris, E, Porto, A, Wandalsen, NF, Sarinho, E, Sano, F, Solé, D, Pitsios, C, Petrodimopoulou, M, Papadopoulou, E, Passioti, M, Kontogianni, M, Adamia, N, Khaleva, E, del Prado, AP, Du Toit, G, Krzych, E, Samolinska-Zawisza, U, Furmanczyk, K, Tomaszewska, A, Raciborski, F, Lipiec, A, Samel-Kowalik, P, Walkiewicz, A, Borowicz, J, Samolinski, B, Nano, AL, Recto, M, Somoza, ML, López, NB, Alzate, DP, Ruano, FJ, Garcimartín, MI, Haroun, E, de la Torre, MV, Rojas, A, Onieva, ML, Canto, G, Rodrigues, A, Forno, A, Cabral, AJ, Gonçalves, R, Vorozhko, I, Sentsova, T, Chernyak, O, Denisova, S, Ilènko, L, Muhortnich, V, Zimmermann, C, Rohrbach, A, Bakhsh, FR, Boudewijn, K, Oomkes-Pilon, A-M, Van Ginkle, D, Šilar, M, Jeverica, A, Vesel, T, Avčin, T, Korošec, P, van der Valk, J, Berends, I, Arends, N, van Maaren, M, Wichers, H, Emons, J, Dubois, A, de Jong, N, Matsyura, O, Besh, L, Huang, C-H, Jan, T-R, Stiefel, G, Tratt, J, Kirk, K, Arasi, S, Caminiti, L, Crisafulli, G, Fiamingo, C, Fresta, J, Pajno, G, Remington, B, Kruizinga, A, Marty Blom, W, Westerhout, J, Bijlsma, S, Blankestijn, M, Otten, H, Klemans, R, Michelsen-Huisman, AD, van Os-Medendorp, H, Kruizinga, AG, Versluis, A, van Duijn, G, de Zeeuw-Brouwer, HM-L, Castenmiller, JJM, Noteborn, HPJM, Houben, GF, Bravin, K, Luyt, D, Javed, B, Couch, P, Munro, C, Padfield, P, Sperrin, M, Byrne, A, Oosthuizen, L, Kelleher, C, Ward, F, Brosnan, N, King, G, Corbet, E, Guzmán, JAH, García, MB, Asensio, O, Navarrete, LV, Larramona, H, Miró, XD, Pyrz, K, Austin, M, Boloh, Y, Galloway, D, Hernandez, P, Hourihane, JOB, Kenna, F, Majkowska-Wojciechowska, B, Regent, L, Themisb, M, Schnadt, S, Semic-Jusufagic, A, Galvin, AD, Kauppila, T, Kuitunen, M, Kitsioulis, NA, Douladiris, N, Kostoudi, S, Manolaraki, I, Mitsias, D, Manousakis, E, Papadopoulos, NG, Knibb, R, Hammond, J, Cooke, R, Yrjänä, J, Hanni, A-M, Vähäsarja, P, Mustonen, O, Dunder, T, Kulmala, P, Lasa, E, D’Amelio, C, Martínez, S, Joral, A, Gastaminza, G, Goikoetxea, MJ, Candy, DCA, Van Ampting, MTJ, Oude Nijhuis, MM, Butt, AM, Peroni, DG, Fox, AT, Knol, J, Michaelis, LJ, Padua, I, Padrao, P, Moreira, P, Barros, R, Sharif, H, Ahmed, M, Gomaa, N, Mens, J, Smit, K, Timmermans, F, Poredoš, T, Jeverica, AK, Sedmak, M, Benedik, E, Accetto, M, Zupančič, M, Yonamine, G, Soldateli, G, Aquilante, B, Pastorino, AC, de Moraes Beck, CL, Gushken, AK, de Barros Dorna, M, dos Santos, CN, Castro, APM, Al-Qahtani, A, Arnaout, R, Khaliq, AR, Amin, R, Sheikh, F, Alvarez, J, Anda, M, Palacios, M, De Prada, M, Ponce, C, Balbino, B, Sibilano, R, Marichal, T, Gaudenzio, N, Karasuyama, H, Bruhns, P, Tsai, M, Reber, LL, Galli, SJ, Ferreira, AR, Cernadas, JR, del Campo García, A, Fernández, SP, Carrera, NS, Sánchez-Cruz, FB, Lorenzo, JRF, Claus, S, Pföhler, C, Ruëff, F, Treudler, R, Jaume, ME, Madroñero, A, Perez, MTG, Julia, JC, Plovdiv, CH, Gethings, L, Langridge, J, Adel-Patient, K, Bernard, H, Barcievic-Jones, I, Sokolova, R, Yankova, R, Ivanovska, M, Murdjeva, M, Popova, T, Dermendzhiev, S, Karjalainen, M, Lehnigk, U, Brown, D, Locklear, JC, Locklear, J, Maris, I, Hourihane, J, Ornelas, C, Caiado, J, Ferreira, MB, Pereira-Barbosa, M, Puente, Y, Daza, JC, Monteseirin, FJ, Ukleja-Sokolowska, N, Gawronska-Ukleja, E, Zbikowska-Gotz, M, Bartuzi, Z, Sokolowski, L, Adams, A, Mahon, B, English, K, Gourdon-Dubois, N, Sellam, L, Pereira, B, Michaud, E, Messaoudi, K, Evrard, B, Fauquert, J-L, Palomares, F, Gomez, G, Rodriguez, MJ, Galindo, L, Molina, A, Paparo, L, Mennini, M, Aitoro, R, Wawrzeńczyk, A, Przybyszewski, M, Sarıcoban, HE, Ugras, M, Yalvac, Z, Flokstra-de Blok, BMJ, van der Velde, JL, Vereda, A, Ippolito, C, Traversa, A, Adriano, D, Bianchi, DM, Gallina, S, Decastelli, L, Makatsori, M, Miles, A, Devetak, SP, Devetak, I, Tabet, SA, Trandbohus, JF, Winther, P, Malling, H-J, Hansen, KS, Garvey, LH, Wang, C-C, Cheng, Y-H, Tung, C-W, Dietrich, M, Marenholz, I, Kalb, B, Grosche, S, Blümchen, K, Schlags, R, Price, M, Rietz, S, Esparza-Gordillo, J, Lau, S, Lee, Y-A, Almontasheri, A, Bahkali, MA, Elshorbagi, S, Alfhaid, A, Altamimi, M, Madbouly, E, Al-Dhekri, H, Arnaout, RK, Basagaña, M, Miquel, S, Bartolomé, B, Brix, B, Rohwer, S, Brandhoff, S, Berger, A, Suer, W, Weimann, A, Bueno, C, Martín-Pedraza, L, Abián, S, Segundo-Acosta, PS, López-Rodríguez, JC, Barderas, R, Batanero, E, Cuesta-Herranz, J, Villalba, MT, Correia, M, Benito-Garcia, F, Arêde, C, Piedade, S, Morais-Almeida, M, Hindley, J, Yarham, R, Kuklinska-Pijanka, A, Gillick, D, Patient, K, Chapman, MD, Miranda, A, Matos, E, Sokolova, A, Rao, H, Baricevic-Jones, I, Smith, F, Xue, W, Magnusdottir, H, Vidarsdottir, AG, Lund, S, Jensen, AB, Ludviksson, BR, Simon, R, Elfont, R, Bennett, S, Voyksner, R, de Lurdes Torre, M, Yürek, S, Faber, MA, Bastiaensen, A, Mangodt, E, van Gasse, A, Decuyper, I, Sabato, V, Hagendorens, MM, Bridts, CH, De Clerck, LS, Ebo, D, Schwarz, S, Ziegert, M, Albroscheit, S, Schwager, C, Kull, S, Behrends, J, Röckendorf, N, Schocker, F, Frey, A, Homann, A, Becker, W-M, Jappe, U, Zaabat, N, Osscini, S, Agabriel, C, Sterling, B, Carsin, A, Liabeuf, V, Maćków, M, Zbróg, A, Bronkowska, M, Courtois, J, Gadisseur, R, Bertholet, C, Lukas, P, Cavalier, E, Delahaut, P, Quinting, B, Gertmo, MB, Hasseus, ET, Barzylovych, V, Oliveira, J, Ensina, LF, Aranda, CS, Dopazo, L, Lopez, R, Perez, R, Santos-Diez, L, Bilbao, A, Garcia, JM, Núñez, IG, Mármol, MÁA, Villarejo, MJB, Martos, JAB, Vergara, MS, García, JMI, Michalska, A, Sergiejko, G, Zacniewski, R, Ghiordanescu, I-M, Deaconu, C, Popescu, M, Bumbacea, RS, Ibranji, A, Nikolla, E, Loloci, G, Juel-Berg, N, Larsen, LF, Poulsen, LK, Marcelino, J, Prata, R, Costa, AC, Duarte, F, Neto, M, Santos, J, Pestana, LC, Sampaio, D, Minale, P, Dignetti, P, Bignardi, D, Nedelea, I, Popescu, F-D, Vieru, M, Secureanu, F-A, Ganea, CS, Vieira, M, Silva, JPM, Watts, T, Watts, S, Lomikovska, M, Peredelskaya, M, Nenasheva, N, Filipovic, I, Zivkovic, Z, Filipovic, D, Higgs, J, Warner, A, and Jones, C
- Published
- 2017
31. Importance du travail du sol : typologie des modes de mise en œuvre et effet sur le rendement des cultures
- Author
-
Roger-Estrade, Jean, Labreuche, J., Boizard, Hubert, Agronomie, Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Station Expérimentale, ARVALIS - Institut du végétal [Paris], Agroressources et Impacts environnementaux (AgroImpact), Institut National de la Recherche Agronomique (INRA), Labreuche, J., Laurent, F., and Roger-Estrade, J.
- Subjects
travail du sol ,rendement ,non labour ,mode de travail du sol ,systèmes de culture ,structure du sol ,[SDV]Life Sciences [q-bio] ,[SDE]Environmental Sciences ,[SDV.BV]Life Sciences [q-bio]/Vegetal Biology - Abstract
CT1 ; EnjS3 ; Département E.A.; National audience
- Published
- 2014
32. Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke
- Author
-
Gonzalez-Valcarcel, J, Sissani, L, Labreuche, J, Bousser, M-G, Chamorro, A, Fisher, M, Ford, I, Fox, KM, Hennerici, MG, Mattle, HP, Rothwell, PM, Steg, PG, Vicaut, E, Amarenco, P, and PERFORM Investigators
- Subjects
Male ,medicine.medical_specialty ,PERFORM Investigators ,Hemorrhage ,Ibuprofen ,030204 cardiovascular system & hematology ,1102 Cardiovascular Medicine And Haematology ,Brain Ischemia ,Brain ischemia ,cardiovascular events ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Recurrence ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,610 Medicine & health ,Stroke ,Acetaminophen ,Aged ,Advanced and Specialized Nursing ,Neurology & Neurosurgery ,business.industry ,organic chemicals ,1103 Clinical Sciences ,Analgesics, Non-Narcotic ,Middle Aged ,antiplatelet agent ,bleeding ,medicine.disease ,Terutroban ,Cardiovascular Diseases ,transient ischemic attack ,Anesthesia ,Female ,Neurology (clinical) ,1109 Neurosciences ,Cardiology and Cardiovascular Medicine ,business ,Major bleeding ,Mace ,medicine.drug - Abstract
Background and Purpose— The presumed safety of paracetamol in high–cardiovascular risk patients has been questioned. We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial. Methods— We performed 2 nested case–control analysis (2153 cases with MACE during trial follow-up and 4306 controls matched on Essen stroke risk score; 809 cases with major bleeding matched with 1616 controls) and a separate time-varying analysis. Results— 12.3% were prescribed paracetamol and 2.5% ibuprofen. Median duration of treatment was 14 (interquartile range 5–145) days for paracetamol and 9 (5–30) days for ibuprofen. Paracetamol, but not ibuprofen, was associated with increased risk of MACE (odds ratio 1.21, 95% confidence interval [CI] 1.04–1.42) or a major bleeding (odds ratio 1.60, 95% CI 1.26–2.03), with no impact of daily dose and duration of paracetamol treatment. Time-varying analysis found an increased risk of MACE with both paracetamol (hazard ratio 1.22, 95% CI 1.05–1.43) and ibuprofen (hazard ratio 1.47, 95% CI 1.06–2.03) and of major bleeding with paracetamol (hazard ratio 1.95, 95% CI 1.45–2.62). Conclusions— There was a weak and inconsistent signal for association between paracetamol or ibuprofen and MACE or major bleeding, which may be related to either a genuine but modest effect of these drugs or to residual confounding. Clinical Trial Registration— http://www.isrctn.com . Unique identifier: ISRCTN66157730.
- Published
- 2015
33. Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)
- Author
-
Soilly, AL, primary, Kossi, DS, additional, Leherle, A, additional, Orng, E, additional, Labreuche, J, additional, Blanc, R, additional, Piotin, M, additional, Lapergue, B, additional, and Baffert, S, additional
- Published
- 2017
- Full Text
- View/download PDF
34. Impact of Modified TICI 3 versus Modified TICI 2b Reperfusion Score to Predict Good Outcome following Endovascular Therapy
- Author
-
Dargazanli, C., primary, Consoli, A., additional, Barral, M., additional, Labreuche, J., additional, Redjem, H., additional, Ciccio, G., additional, Smajda, S., additional, Desilles, J.P., additional, Taylor, G., additional, Preda, C., additional, Coskun, O., additional, Rodesch, G., additional, Piotin, M., additional, Blanc, R., additional, and Lapergue, B., additional
- Published
- 2016
- Full Text
- View/download PDF
35. Which factors influence the resort to surrogate consent in stroke trials, and what are the patient outcomes in this context?
- Author
-
Mendyk, A-M. (Anne-Marie), Labreuche, J. (Julien), Henon, H. (Hilde), Destee, M. (Marie), Cordonnier, C. (Charlotte), Duhamel, A. (Alain), LEYS, D. (Didier), Bordet, R. (Regis), Department of Neurology [Lille], Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Clinical Research Federation [Lille], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Statistics [Lille], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Emergency [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Pharmacology [Lille], This study was funded by the French Ministry of Health (as part of the PHRC programme), the French Ministry of Research and the Foundation Coeur & Artères., Bodescot, Myriam, Département de neurologie [Lille], Département de Pharmacologie Médicale [Lille] (Pôle Recherche), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Faculté de Médecine Henri Warembourg - Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Santé Publique : épidémiologie et qualité des soins (EA 2694), Faculté de Médecine Henri Warembourg - Université de Lille-Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), CHU Lille, CNRS, Inserm, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U1171, Santé publique : épidémiologie et qualité des soins - EA 2694, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, and Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
- Subjects
Male ,Biomedical Research ,Research Subjects ,Decision Making ,Severity of Illness Index ,Health(social science) ,Cognition ,Aphasia ,Humans ,Aged ,Aged, 80 and over ,Informed Consent ,Patient Selection ,Health Policy ,[SCCO.NEUR]Cognitive science/Neuroscience ,[SCCO.NEUR] Cognitive science/Neuroscience ,Age Factors ,Middle Aged ,[SDV.ETH] Life Sciences [q-bio]/Ethics ,Proxy ,United States ,humanities ,[SDV.ETH]Life Sciences [q-bio]/Ethics ,Stroke ,Issues, ethics and legal aspects ,Research Design ,[SCCO.PSYC] Cognitive science/Psychology ,[SCCO.PSYC]Cognitive science/Psychology ,Female ,Cognition Disorders ,Research Article - Abstract
International audience; BACKGROUND:The provision of informed consent is a prerequisite for inclusion of a patient in a clinical research project. In some countries, the legislation on clinical research authorizes a third person to provide informed consent if the patient is unable to do so directly (i.e. surrogate consent). This is the case during acute stroke, when the symptoms may prevent the patient from providing informed consent and thus require a third party to be approached. Identification of factors associated with the medical team's decision to resort to surrogate consent may (i) help the care team during the inclusion process and (ii) enable the patient's family circle to be better informed (and thus feel less guilty) about providing surrogate consent.METHODS:Patients included in the BIOSTROKE cohort (initially dedicated to the analysis of factors influencing stroke severity) were divided into two groups: those having provided informed consent directly and those for whom a third party (such as a family member) had provided surrogate consent. We compared the groups in terms of the initial clinical characteristics (age, gender, type of stroke, severity on the National Institutes of Health Stroke Scale (NIHSS), pre-stroke cognitive status according to the Informant Questionnaire on Cognitive Decline in the Elderly, and the stroke's aetiology) and the functional and cognitive impairments (according to the NIHSS, the modified Rankin score (mRS) and the Mini Mental State Examination) on post-stroke days 8 and 90.RESULTS:Three hundred and ninety five patients were included (mean ± SD age: 67 ± 15 years; 53% males). Surrogate consent had been obtained in 228 cases, and 167 patients had provided consent themselves. The patients included with surrogate consent were likely to be older and more aphasic, with a pre-existing cognitive disorder and more severe stroke (relative to the patients having provided consent). In terms of recovery, the patients included with surrogate consent had a worse functional prognosis (day 90 mRS ≥3: 57.6%, compared with 16.8% in patients having provided consent themselves; p < 0.0001) and a worse cognitive prognosis (day 90 MMS < 24: 15.4% and 4.8%, respectively; p < 0.002). The mortality rate was significantly higher in the surrogate consent group.CONCLUSIONS:We found that in addition to age, aphasia and stroke severity, pre-stroke cognitive status is a factor that should prompt the care team to consider requesting surrogate consent for participation in a clinical study. Given that the unfavourable outcome in patients with surrogate consent is often due to their initial clinical state (rather than inclusion in a trial per se), the issue of the family's feelings of guilt (and how to avoid these feelings) should be further addressed.
- Published
- 2015
36. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
- Author
-
Amarenco, P., primary, Lavallee, P.C., additional, and Labreuche, J., additional
- Published
- 2016
- Full Text
- View/download PDF
37. A Direct Aspiration, First Pass Technique (ADAPT) versus Stent Retrievers for Acute Stroke Therapy: An Observational Comparative Study
- Author
-
Lapergue, B., primary, Blanc, R., additional, Guedin, P., additional, Decroix, J.-P., additional, Labreuche, J., additional, Preda, C., additional, Bartolini, B., additional, Coskun, O., additional, Redjem, H., additional, Mazighi, M., additional, Bourdain, F., additional, Rodesch, G., additional, and Piotin, M., additional
- Published
- 2016
- Full Text
- View/download PDF
38. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
- Author
-
Desoutter, J, primary, Gay, J, additional, Berthon, C, additional, Ades, L, additional, Gruson, B, additional, Geffroy, S, additional, Plantier, I, additional, Marceau, A, additional, Helevaut, N, additional, Fernandes, J, additional, Bemba, M, additional, Stalnikiewicz, L, additional, Frimat, C, additional, Labreuche, J, additional, Nibourel, O, additional, Roumier, C, additional, Figeac, M, additional, Fenaux, P, additional, Quesnel, B, additional, Renneville, A, additional, Duhamel, A, additional, and Preudhomme, C, additional
- Published
- 2015
- Full Text
- View/download PDF
39. Impact of diffusion-weighted imaging lesion volume on the success of endovascular reperfusion therapy
- Author
-
Becquemont, Laurent, Benattar-Zibi, Linda, Bertin, Philippe, Berrut, Gilles, Corruble, Emmanuelle, Danchin, Nicolas, Delespierre, Tiba, Derumeaux, Geneviève, Falissard, Bruno, Forette, Francoise, Hanon, Olivier, Pasquier, Florence, Pinget, Michel, Ourabah, Rissane, Piedvache, Celine, Olivot, J.-M., Mosimann, P., Labreuche, J., Inoue, M., Meseguer, E., Desilles, J.-P., Rouchaud, A., Klein, I., Straka, M., Bammer, R., Mlynash, M., Amarenco, P., Albers, G., Mazighi, M., Service de génétique moléculaire, pharmacogénétique et hormonologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Orange Labs [Cesson-Sévigné], Orange Labs, Laboratoire Motricité, Interactions, Performance (UPRES EA 4334), Université de Nantes (UN), Service de psychiatrie [Le Kremlin-Bicêtre], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Dpt Gériatrie [CHU Broca], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Service de Neurologie [Lille], Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Diabète et thérapeutique : îlots pancréatiques et innovations technologiques (DIATHEC), Université de Strasbourg (UNISTRA), Hôpital Bicêtre, ARVALIS - Institut du végétal [Paris], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), ROTHSCHILD FOUNDATION, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de neurologie [Lille], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), and Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Subjects
Male ,medicine.medical_specialty ,Middle Cerebral Artery ,medicine.medical_treatment ,Arterial Occlusive Diseases ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Article ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Fibrinolytic Agents ,Interquartile range ,Modified Rankin Scale ,medicine.artery ,Medicine ,Humans ,Thrombolytic Therapy ,cardiovascular diseases ,Prospective Studies ,Registries ,Stroke ,ComputingMilieux_MISCELLANEOUS ,Aged ,Advanced and Specialized Nursing ,Aged, 80 and over ,business.industry ,Thrombolysis ,Middle Aged ,medicine.disease ,Diffusion Magnetic Resonance Imaging ,Treatment Outcome ,Tissue Plasminogen Activator ,Middle cerebral artery ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Female ,Neurology (clinical) ,Radiology ,Internal carotid artery ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,Fibrinolytic agent ,Carotid Artery, Internal - Abstract
Background and Purpose— Diffusion-weighted imaging (DWI) lesion volume is associated with poor outcome after thrombolysis, and it is unclear whether endovascular therapies are beneficial for large DWI lesion. Our aim was to assess the impact of pretreatment DWI lesion volume on outcomes after endovascular therapy, with a special emphasis on patients with complete recanalization. Methods— We analyzed data collected between April 2007 and November 2011 in a prospective clinical registry. All acute ischemic stroke patients with complete occlusion of internal carotid artery or middle cerebral artery treated by endovascular therapy were included. DWI lesion volumes were measured by the RAPID software. Favorable outcome was defined by modified Rankin Scale of 0 to 2 at 90 days. Results— A total of 139 acute ischemic stroke patients were included. Median DWI lesion volume was 14 cc (interquartile range, 5–43) after a median onset time to imaging of 110 minutes (interquartile range, 77–178). Higher volume was associated with less favorable outcome (adjusted odds ratio, 0.55; 95% confidence interval, 0.31–0.96). A complete recanalization was achieved in 65 (47%) patients after a median onset time of 238 minutes (interquartile range, 206–285). After adjustment for volume, complete recanalization was associated with more favorable outcome (adjusted odds ratio, 6.32; 95% confidence interval, 2.90–13.78). After stratification of volume by tertiles, complete recanalization was similarly associated with favorable outcome in the upper 2 tertiles ( P Conclusions— Our results emphasize the importance of initial DWI volume and recanalization on clinical outcome after endovascular treatment. Large DWI lesions may still benefit from recanalization in selected patients.
- Published
- 2013
40. Soil environmental conditions rather than denitrifier abundance and diversity drive potential denitrification after changes in land uses
- Author
-
Attard, E, Recous, S, Chabbi, A, De Berranger, C, Guillaumaud, N, Labreuche, J, Philippot, L, Schmid, B, Le Roux, X, University of Zurich, Le Roux, X, Laboratoire d'Ecologie Microbienne - UMR 5557 (LEM), Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Vétérinaire de Lyon (ENVL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Recherche Agronomique (INRA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Unité d'Agronomie de Laon-Reims-Mons (AGRO-LRM), Institut National de la Recherche Agronomique (INRA), UEFE, INRA Lusignan, UR 0004 Unité de Recherche Écophysiologie des Plantes Fourragères, Institut National de la Recherche Agronomique (INRA)-Environnement et Agronomie (E.A.)-Unité de Recherche Écophysiologie des Plantes Fourragères (UEPF), ARVALIS - Institut du végétal [Paris], Microbiologie du Sol et de l'Environnement (MSE), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB), UMR179 Seqbio, Institut d'électronique fondamentale (IEF), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Ecologie microbienne ( EM ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Vétérinaire de Lyon ( ENVL ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Recherche Agronomique ( INRA ) -VetAgro Sup ( VAS ), Unité d'Agronomie de Laon-Reims-Mons ( AGRO-LRM ), Institut National de la Recherche Agronomique ( INRA ), Institut National de la Recherche Agronomique ( INRA ) -Environnement et Agronomie ( E.A. ) -Unité de Recherche Écophysiologie des Plantes Fourragères ( UEPF ), Microbiologie du Sol et de l'Environnement ( MSE ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ), Institut d'électronique fondamentale ( IEF ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Agrosystèmes et impacts environnementaux carbone-azote (Agro-Impact), Unité Expérimentale Fourrages et Environnement de Lusignan (UEFE), Unité de recherche d'Écophysiologie des Plantes Fourragères (UEPF), French Ministry of Environment and Sustainable Development (MEDD), ECCO-PNBC, INRA, and Region Poitou-Charentes
- Subjects
N2O emissions ,[ SDV ] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,carbon ,2306 Global and Planetary Change ,temporary grasslan ,use change ,soil microbial ecology ,2300 General Environmental Science ,land ,10127 Institute of Evolutionary Biology and Environmental Studies ,soil organic ,no tillage ,2304 Environmental Chemistry ,soil C and N dynamics ,570 Life sciences ,biology ,590 Animals (Zoology) ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,2303 Ecology ,ComputingMilieux_MISCELLANEOUS ,biodiversity - Abstract
cited By 96; International audience; no abstract
- Published
- 2011
41. Dégradation physique des sols agricoles et forestiers liée au tassement : principaux résultats du projet GESSOL ADD-DST
- Author
-
Roger-Estrade, Jean, Adamiade, Vincent, Arrouays, Dominique, Bartoli, M., Baranger, Edouard, Boizard, Hubert, Brêthes, A., Brisson, Nadine, Capowiez, Yvan, Chanzy, Andre, Chaplain, Véronique, Cousin, Isabelle, Cosenza, Philippe, Cui, Kai, Cui, Y.J., Debuisson, S., Defossez, Pauline, Gerard, Françoise, Jayet, Pierre-Alain, Labreuche, J., Le Bas, Christine, Lefevre, Yves, Léonard, Joël, Leveque, E., Lévêque, F., Mary, Bruno, Mumen, M., Ranger, Jacques, Tabbagh, Alain, Tabbagh, J., Tang, Anh Minh, Tessier, Daniel, Richard, Guy, Agronomie, Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Agrosystèmes et impacts environnementaux carbone-azote (Agro-Impact), Institut National de la Recherche Agronomique (INRA), InfoSol (InfoSol), Office National des Forêts (ONF), Economie Publique (ECO-PUB), Agroclim (AGROCLIM), Unité de recherche Plantes et Systèmes de Culture Horticoles (PSH), Environnement Méditerranéen et Modélisation des Agro-Hydrosystèmes (EMMAH), Avignon Université (AU)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité de recherche Science du Sol (USS), Université Paris Descartes - Paris 5 (UPD5), École des Ponts ParisTech (ENPC), Comité Interprofessionnel du Vin de Champagne (CIVC), Unité de recherche Biogéochimie des Ecosystèmes Forestiers (BEF), ARVALIS - Institut du végétal [Paris], Institut Technique de la Betterave (ITB), Université de La Rochelle (ULR), Centre National de la Recherche Scientifique (CNRS), Ministère en charge de l’Environnement (programme GESSOL2 « Impact des pratiques agricoles sur le sol et les eaux »), and Agence Nationale de la Recherche (Programme « Agriculture et Développement Durable » [ANR-05-PADD-013]).
- Subjects
tassement ,conséquence agri-environnementale ,méthode géophysique ,dst ,gessol ,soil compaction ,mapping ,monitoring ,modelling ,geophysical method ,environmental impact ,PEDOLOGIE ,sol ,[SDU.STU]Sciences of the Universe [physics]/Earth Sciences ,tassement du sol ,érosion ,[SDV.SA.SDS]Life Sciences [q-bio]/Agricultural sciences/Soil study ,Sciences de la Terre ,biodiversité ,pratique agri-environnementale ,sol agricole ,modélisation ,Environmental and Society ,[SDE.ES]Environmental Sciences/Environmental and Society ,environnement ,prévention ,dégradation du sol ,Earth Sciences ,cartographie ,carbone ,Environnement et Société ,europe ,sol forestier ,france - Abstract
La dégradation physique des sols agricoles et forestiers liée au tassement lors des passages d’engins est une préoccupation importante des acteurs de l’agriculture et de la forêt. Mais au-delà de ce cercle, elle concerne également tous ceux qui se préoccupent des conséquences environnementales de l’agriculture et de la gestion forestière. En effet, le tassement des sols modifie a des conséquences lourdes sur plusieurs processus tels que l’érosion hydrique, la dénitrification, le stockage du carbone, la préservation de la biodiversité, la production. Dans ce cadre, le projet DST (Dégradation physique des Sols agricoles et forestiers liée au Tassement) proposait cinq volets de recherche : impact, prévision, prévention, suivi et cartographie du tassement en France métropolitaine. Il a reposé sur l’utilisation de modèles de tassement des sols et de fonctionnement du système sol/plante pour étudier les conséquences sur les cultures et l’environnement, via la modification des propriétés (stockage, transfert, mécaniques) des sols. Ce projet transversal, associant des laboratoires de recherche travaillant en agriculture, en géophysique ou en génie civil et des organismes professionnels, s’est aussi appuyé sur des expérimentations variées, en laboratoire et sur le terrain. Les principaux résultats sont présentés dans cet article. Ils concernent : (i) l’impact du tassement, avec la mise en évidence d’un seuil d’indice des vides en sol limoneux (0,15 m3.m 3 dans les sols limoneux), au-delà duquel les performances des cultures et les propriétés hydrodynamiques sont à coup sûr affectées, (ii) la modélisation, le projet ayant débouché sur la mise au point d’un modèle 2-D de prévision de la déformation des sols, (iii) le suivi, avec l’évaluation de méthodes géophysiques, non destructrices, permettant la cartographie des zones tassées, (iv) la prévention, à travers le développement d’un outil de prévision de l’humidité du sol et des jours disponibles et, (v) la cartographie des zones à risques en France., Physical degradation of agricultural and forest soils due to compaction is an important concern for the actors in agriculture, forest and environment. Many questions are still pending on the importance of this degradation, the evaluation of its impact on environment, the effect of changes of climate and practices, its natural remediation. The DST (Agricultural and Forest Soil Degradation induced by Compaction ?) project has proposed a research action on soil compaction in metropolitan France in order to : quantify the impacts of soil compaction on important soil environmental functions ; identify the conditions leading to compaction ; prevent the occurrence of these conditions ; monitor the evolution of soil structure after compaction. The project was structured in five working packages : impact, prediction, prevention, follow-up and cartography. It was based on modelling (hydrology, soil deformation, soil-crop interactions models) to study the occurrence of compaction and its impacts on crop growth and the environment. It also aimed at developing non-destructive methods to monitor soil structure deformation. The project associated research laboratories working in agriculture, geophysics or civil engineering and extension services members and was also based on field and laboratory experimentations, performed in various conditions (field crops, vineyards, forests). Mains results concerned : (i) impacts of compaction, as we demonstrated the existence of a threshold value for the structural void ratio (0,15 m3m3 in loamy soils) beyond which crop performances and hydrological properties are systematically affected ; (ii) modelling, with a 2-D model of soil deformation ; (iii) compaction assessment, based on non-destructive geophysical methods ; (iv) prevention of compaction, with a predictive model of soil water content and (v) mapping of compaction risks in France, based on the knowledge acquired during the project., La degradación física de los suelos agrícolas y forestales ligada a la compactación durante los pasajes de maquinarias está una preocupación importante de los actores de la agricultura y de la gestión forestal. Pero más allá de este círculo, concierne igualmente todos los que se preocupan de las consecuencias ambientales de la agricultura y de la gestión forestal. En efecto, la compactación de los suelos modifica sus propiedades y así varias funciones importantes para los procesos tales que erosión hídrica, denitrificación, almacenamiento del carbono, preservación de la biodiversidad. En este cuadro, el proyecto DST propuso cinco direcciones de investigación : impacto, previsión, prevención, seguimiento y cartografía de la compactación. Se basó en la utilización de modelos de compactación de los suelos y de funcionamiento del sistema para estudiar las consecuencias sobre los cultivos y el medio ambiente, vía la modificación de las propiedades (almacenamiento, transferencia, mecánicas) de los suelos. Este proyecto transversal, que asocia laboratorios de investigación que trabajan en agricultura, geofísica, o ingeniera civil y los organismos profesionales, se apoyo también sobre experimentaciones variadas, en laboratorio y en el campo. En este articulo se presenta los principales resultados que conciernen : (i) el impacto de la compactación, con la puesta en evidencia de un umbral de índice de vacios en suelo limoso, más allá del cual las performances de los cultivos y las propiedades hidrodinámicas están, desde luego, impactadas, (ii) la modelización, el proyecto desemboco sobre la realización de un modelo 2-D de previsión de la deformación de los suelos, (iii) el seguimiento, con la evaluación de métodos geofísicos, no destructivos que permiten la cartografía de las zonas compactadas, (iv) la prevención, a través del desarrollo de una herramienta de previsión de la humedad del suelo y de los días disponibles y (v) la cartografía de las zonas con riesgos en Francia.
- Published
- 2011
42. Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study
- Author
-
Merwick, A, Albers, G, Amarenco, P, Arsava, E, Ay, H, Calvet, D, Coutts, S, Cucchiara, B, Demchuk, A, Furie, K, Giles, M, Labreuche, J, Lavallée, P, Mas, J, Olivot, J, Purroy, F, Rothwell, P, Saver, J, Sheehan, O, Stack, J, Walsh, C, and Kelly, P
- Subjects
Male ,Internationality ,Time Factors ,Age Factors ,Brain ,Blood Pressure ,Middle Aged ,Severity of Illness Index ,Stroke ,Review Literature as Topic ,Diffusion Magnetic Resonance Imaging ,Ischemic Attack, Transient ,Risk Factors ,Hypertension ,Diabetes Mellitus ,Humans ,Carotid Stenosis ,Female ,Aged ,Follow-Up Studies - Abstract
BACKGROUND: The ABCD² score improves stratification of patients with transient ischaemic attack by early stroke risk. We aimed to develop two new versions of the score: one that was based on preclinical information and one that was based on imaging and other secondary care assessments. METHODS: We analysed pooled data from patients with clinically defined transient ischaemic attack who were investigated while in secondary care. Items that contribute to the ABCD² score (age, blood pressure, clinical weakness, duration, and diabetes), other clinical variables, carotid stenosis, and abnormal acute diffusion-weighted imaging (DWI) were recorded and were included in multivariate logistic regression analysis of stroke occurrence at early time intervals after onset of transient ischaemic attack. Scores based on the findings of this analysis were validated in patients with transient ischaemic attack from two independent population-based cohorts. FINDINGS: 3886 patients were included in the study: 2654 in the derivation sample and 1232 in the validation sample. We derived the ABCD³ score (range 0-9 points) by assigning 2 points for dual transient ischaemic attack (an earlier transient ischaemic attack within 7 days of the index event). C statistics (which indicate discrimination better than chance at >0·5) for the ABCD³ score were 0·78 at 2 days, 0·80 at 7 days, 0·79 at 28 days, and 0·77 at 90 days, compared with C statistics for the ABCD² score of 0·71 at 2 days (p=0·083), 0·71 at 7 days (p=0·012), 0·71 at 28 days (p=0·021), and 0·69 at 90 days (p=0·018). We included stenosis of at least 50% on carotid imaging (2 points) and abnormal DWI (2 points) in the ABCD³-imaging (ABCD³-I) score (0-13 points). C statistics for the ABCD³-I score were 0·90 at 2 days (compared with ABCD² score p=0·035), 0·92 at 7 days (p=0·001), 0·85 at 28 days (p=0·028), and 0·79 at 90 days (p=0·073). The 90-day net reclassification improvement compared with ABCD² was 29·1% for ABCD³ (p=0·0003) and 39·4% for ABCD³-I (p=0·034). In the validation sample, the ABCD³ and ABCD³-I scores predicted early stroke at 7, 28, and 90 days. However, discrimination and net reclassification of patients with early stroke were similar with ABCD³ compared with ABCD². INTERPRETATION: The ABCD³-I score can improve risk stratification after transient ischaemic attack in secondary care settings. However, use of ABCD³ cannot be recommended without further validation. FUNDING: Health Research Board of Ireland, Irish Heart Foundation, and Irish National Lottery.
- Published
- 2010
43. PMD77 - Cost-Effectiveness of A Direct Aspiration First Pass Technique (ADAPT) For Thrombectomy Revascularization of Large Vessel Occlusion In Acute Ischemic Stroke (French Health Ministry Prme 16-0020)
- Author
-
Soilly, AL, Kossi, DS, Leherle, A, Orng, E, Labreuche, J, Blanc, R, Piotin, M, Lapergue, B, and Baffert, S
- Published
- 2017
- Full Text
- View/download PDF
44. Epidemiology of age-related-macular-degeneration in north of France
- Author
-
DURIEUX, P, primary, DELEMOTTE, A, additional, LABREUCHE, J, additional, ROULAND, J, additional, and LABALETTE, P, additional
- Published
- 2014
- Full Text
- View/download PDF
45. Effets des techniques culturales sans labour sur le stockage de carbone dans le sol en contexte climatique tempéré
- Author
-
Metay, A, primary, Mary, B, additional, Arrouays, D, additional, Labreuche, J, additional, Martin, M, additional, Nicolardot, B, additional, and Germon, J -C, additional
- Published
- 2009
- Full Text
- View/download PDF
46. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review
- Author
-
Meseguer, E., primary, Labreuche, J., additional, Olivot, J. M., additional, Abboud, H., additional, Lavallee, P. C., additional, Simon, O., additional, Cabrejo, L., additional, Echeverria, A., additional, Klein, I. F., additional, Mazighi, M., additional, and Amarenco, P., additional
- Published
- 2007
- Full Text
- View/download PDF
47. Outcomes of mechanical endovascular therapy for acute ischemic stroke: a clinical registry study and systematic review.
- Author
-
Rouchaud A, Mazighi M, Labreuche J, Meseguer E, Serfaty JM, Laissy JP, Lavallée PC, Cabrejo L, Guidoux C, Lapergue B, Klein IF, Olivot JM, Abboud H, Simon O, Schouman-Claeys E, Amarenco P, Rouchaud, Aymeric, Mazighi, Mikael, Labreuche, Julien, and Meseguer, Elena
- Published
- 2011
- Full Text
- View/download PDF
48. Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients.
- Author
-
Giles MF, Albers GW, Amarenco P, Arsava MM, Asimos A, Ay H, Calvet D, Coutts S, Cucchiara BL, Demchuk AM, Johnston SC, Kelly PJ, Kim AS, Labreuche J, Lavallee PC, Mas JL, Merwick A, Olivot JM, Purroy F, and Rosamond WD
- Published
- 2010
- Full Text
- View/download PDF
49. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study.
- Author
-
Klein IF, Lavallée PC, Mazighi M, Schouman-Claeys E, Labreuche J, Amarenco P, Klein, Isabelle F, Lavallée, Philippa C, Mazighi, Mikael, Schouman-Claeys, Elisabeth, Labreuche, Julien, and Amarenco, Pierre
- Published
- 2010
- Full Text
- View/download PDF
50. Prevalence of embolic signals in acute coronary syndromes.
- Author
-
Meseguer E, Labreuche J, Durdilly C, Echeverría A, Lavallee PC, Ducrocq G, Touboul PJ, Steg PG, Amarenco P, Meseguer, Elena, Labreuche, Julien, Durdilly, Cloe, Echeverría, Amaya, Lavallee, Philippa C, Ducrocq, Gregory, Touboul, Pierre-Jean, Steg, Philippe Gabriel, and Amarenco, Pierre
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.